{
  "compound_prioritization": {
    "result": {
      "reasoning": "Tanespimycin demonstrates strong preclinical efficacy in multiple animal models of cardiac fibrosis and heart failure, with relevant mechanistic insights into its anti-fibrotic actions. This suggests significant therapeutic potential for cardiac fibrosis. However, a critical limitation for prioritization is the complete absence of toxicity data in the provided assessment (Percent Remaining Cells: None). While tanespimycin is a known drug with an established safety profile from its development in oncology, the lack of specific toxicity data within this assessment makes a comprehensive risk-benefit analysis for cardiac fibrosis indications impossible. Therefore, despite promising efficacy, the compound cannot be highly prioritized without a clear understanding of its safety profile. Further toxicity screening is essential before advancing this compound.",
      "priority_score": 0.45,
      "confidence": 0.4
    },
    "sub_agents": {
      "cf_efficacy": {
        "result": {
          "trajectory": {
            "thought_0": "I need to assess the efficacy of tanespimycin for reversing cardiac fibrosis. My first step is to find information about tanespimycin, starting with its ChEMBL ID, which will allow me to explore its bioactivities and potential mechanisms of action related to cardiac fibrosis.",
            "tool_name_0": "CHEMBL__search_compounds",
            "tool_args_0": {
              "request": {
                "query": "tanespimycin"
              }
            },
            "observation_0": "{\n  \"molecules\": [\n    {\n      \"atc_classifications\": [],\n      \"availability_type\": -1,\n      \"biotherapeutic\": null,\n      \"black_box_warning\": 0,\n      \"chebi_par_id\": null,\n      \"chemical_probe\": 0,\n      \"chirality\": -1,\n      \"cross_references\": [],\n      \"dosed_ingredient\": false,\n      \"first_approval\": null,\n      \"first_in_class\": -1,\n      \"helm_notation\": null,\n      \"indication_class\": null,\n      \"inorganic_flag\": -1,\n      \"max_phase\": null,\n      \"molecule_chembl_id\": \"CHEMBL4786163\",\n      \"molecule_hierarchy\": {\n        \"active_chembl_id\": \"CHEMBL4786163\",\n        \"molecule_chembl_id\": \"CHEMBL4786163\",\n        \"parent_chembl_id\": \"CHEMBL4786163\"\n      },\n      \"molecule_properties\": {\n        \"alogp\": \"2.54\",\n        \"aromatic_rings\": 0,\n        \"cx_logd\": \"2.57\",\n        \"cx_logp\": \"2.57\",\n        \"cx_most_apka\": \"12.78\",\n        \"cx_most_bpka\": null,\n        \"full_molformula\": \"C31H43N3O8\",\n        \"full_mwt\": \"585.70\",\n        \"hba\": 9,\n        \"hba_lipinski\": 11,\n        \"hbd\": 4,\n        \"hbd_lipinski\": 5,\n        \"heavy_atoms\": 42,\n        \"molecular_species\": \"NEUTRAL\",\n        \"mw_freebase\": \"585.70\",\n        \"mw_monoisotopic\": \"585.3050\",\n        \"np_likeness_score\": \"2.38\",\n        \"num_lipinski_ro5_violations\": 2,\n        \"num_ro5_violations\": 1,\n        \"psa\": \"166.28\",\n        \"qed_weighted\": \"0.27\",\n        \"ro3_pass\": \"N\",\n        \"rtb\": 6\n      },\n      \"molecule_structures\": {\n        \"canonical_smiles\": \"C=CCNC1=C2C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(/C)[C@H](OC(N)=O)[C@@H](OC)/C=C\\\\C=C(\\\\C)C(=O)NC(=CC1=O)C2=O\",\n        \"molfile\": \"\\n     RDKit          2D\\n\\n 42 43  0  0  1  0  0  0  0  0999 V2000\\n   12.6717    4.0607    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n   11.7136    3.7743    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n   10.9865    4.4608    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n   10.0284    4.1744    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0\\n    9.3013    4.8610    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    8.3432    4.5745    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    8.1763    3.5886    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    7.6941    2.7125    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    8.4774    2.0908    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    6.9504    2.0440    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    6.0281    1.6575    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    6.2552    0.6836    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\\n    5.5254    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    5.0300    1.5961    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    4.9239    0.6018    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\\n    4.0673    1.8668    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    3.6398    0.9627    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    3.2474    2.4392    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    2.6615    3.2496    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    1.7647    2.8073    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    2.3751    4.2077    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    1.3827    4.0852    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\\n    0.9925    3.1645    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    0.0000    3.0420    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0\\n    1.5948    2.3662    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\\n    2.4200    5.2067    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    2.7913    6.1352    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    3.4475    6.8898    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    4.3155    7.3863    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    5.2986    7.5695    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    5.2822    8.5693    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    6.2872    7.4188    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    6.6008    8.3683    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\\n    7.1711    6.9511    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0\\n    7.8471    6.2340    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    8.8052    6.5204    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    9.5323    5.8339    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n   10.4904    6.1203    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\\n    7.6161    5.2611    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    6.6580    4.9747    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\\n    1.4426    5.4178    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\\n    0.7711    4.6768    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n  1  2  2  0\\n  2  3  1  0\\n  3  4  1  0\\n  4  5  1  0\\n  5  6  2  0\\n  6  7  1  0\\n  7  8  1  0\\n  8  9  1  1\\n  8 10  1  0\\n 10 11  1  0\\n 11 12  1  6\\n 12 13  1  0\\n 11 14  1  0\\n 14 15  1  6\\n 14 16  1  0\\n 16 17  1  1\\n 16 18  1  0\\n 18 19  2  0\\n 19 20  1  0\\n 19 21  1  0\\n 21 22  1  6\\n 22 23  1  0\\n 23 24  1  0\\n 23 25  2  0\\n 21 26  1  0\\n 26 27  1  0\\n 27 28  2  0\\n 28 29  1  0\\n 29 30  2  0\\n 30 31  1  0\\n 30 32  1  0\\n 32 33  2  0\\n 32 34  1  0\\n 34 35  1  0\\n 35 36  2  0\\n 36 37  1  0\\n 37  5  1  0\\n 37 38  2  0\\n 35 39  1  0\\n 39  6  1  0\\n 39 40  2  0\\n 26 41  1  1\\n 41 42  1  0\\nM  END\\n> <chembl_id>\\nCHEMBL4786163\\n\\n> <chembl_pref_name>\\nNone\",\n        \"standard_inchi\": \"InChI=1S/C31H43N3O8/c1-8-12-33-26-21-13-17(2)14-25(41-7)27(36)19(4)15-20(5)29(42-31(32)39)24(40-6)11-9-10-18(3)30(38)34-22(28(21)37)16-23(26)35/h8-11,15-17,19,24-25,27,29,33,36H,1,12-14H2,2-7H3,(H2,32,39)(H,34,38)/b11-9-,18-10-,20-15-/t17-,19+,24+,25+,27-,29+/m1/s1\",\n        \"standard_inchi_key\": \"AYUNIORJHRXIBJ-BGGMETADSA-N\"\n      },\n      \"molecule_synonyms\": [],\n      \"molecule_type\": \"Unknown\",\n      \"natural_product\": 1,\n      \"oral\": false,\n      \"orphan\": -1,\n      \"parenteral\": false,\n      \"polymer_flag\": 0,\n      \"pref_name\": null,\n      \"prodrug\": -1,\n      \"score\": 37.0,\n      \"structure_type\": \"MOL\",\n      \"therapeutic_flag\": false,\n      \"topical\": false,\n      \"usan_stem\": null,\n      \"usan_stem_definition\": null,\n      \"usan_substem\": null,\n      \"usan_year\": null,\n      \"withdrawn_flag\": false\n    },\n    {\n      \"atc_classifications\": [],\n      \"availability_type\": null,\n      \"biotherapeutic\": null,\n      \"black_box_warning\": 0,\n      \"chebi_par_id\": 64153,\n      \"chemical_probe\": 0,\n      \"chirality\": 1,\n      \"cross_references\": [],\n      \"dosed_ingredient\": false,\n      \"first_approval\": null,\n      \"first_in_class\": 0,\n      \"helm_notation\": null,\n      \"indication_class\": null,\n      \"inorganic_flag\": 0,\n      \"max_phase\": \"3.0\",\n      \"molecule_chembl_id\": \"CHEMBL109480\",\n      \"molecule_hierarchy\": {\n        \"active_chembl_id\": \"CHEMBL109480\",\n        \"molecule_chembl_id\": \"CHEMBL109480\",\n        \"parent_chembl_id\": \"CHEMBL109480\"\n      },\n      \"molecule_properties\": {\n        \"alogp\": \"2.54\",\n        \"aromatic_rings\": 0,\n        \"cx_logd\": \"2.57\",\n        \"cx_logp\": \"2.57\",\n        \"cx_most_apka\": \"12.78\",\n        \"cx_most_bpka\": null,\n        \"full_molformula\": \"C31H43N3O8\",\n        \"full_mwt\": \"585.70\",\n        \"hba\": 9,\n        \"hba_lipinski\": 11,\n        \"hbd\": 4,\n        \"hbd_lipinski\": 5,\n        \"heavy_atoms\": 42,\n        \"molecular_species\": \"NEUTRAL\",\n        \"mw_freebase\": \"585.70\",\n        \"mw_monoisotopic\": \"585.3050\",\n        \"np_likeness_score\": \"2.38\",\n        \"num_lipinski_ro5_violations\": 2,\n        \"num_ro5_violations\": 1,\n        \"psa\": \"166.28\",\n        \"qed_weighted\": \"0.27\",\n        \"ro3_pass\": \"N\",\n        \"rtb\": 6\n      },\n      \"molecule_structures\": {\n        \"canonical_smiles\": \"C=CCNC1=C2C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\\\\C)[C@H](OC(N)=O)[C@@H](OC)/C=C\\\\C=C(/C)C(=O)NC(=CC1=O)C2=O\",\n        \"molfile\": \"\\n     RDKit          2D\\n\\n 42 43  0  0  0  0  0  0  0  0999 V2000\\n   -3.0155   -9.9521    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n   -3.0107  -10.7771    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n   -1.5752   -9.9474    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n   -2.2856  -11.1902    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n   -2.2875  -12.0239    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n   -1.5769  -12.4343    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n   -1.5771  -13.2676    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n   -0.8673  -13.6831    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n   -0.1346  -13.2613    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n   -1.5772  -10.7724    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\\n   -0.8598   -9.5365    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n   -0.8579   -8.7115    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n   -1.5714   -8.2974    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n   -1.5695   -7.4724    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\\n   -2.2868   -8.7082    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n   -2.2887   -9.5332    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n   -0.1463   -9.9507    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0\\n    0.5691   -9.5398    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    1.2802   -9.9521    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    0.5709   -8.7148    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\\n    1.2787  -10.7771    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    1.9954   -9.5410    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    1.9924  -11.1910    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    1.9908  -12.0160    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    1.2756  -12.4271    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    1.2741  -13.2521    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n   -0.1335  -12.4363    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n   -0.8677  -12.0146    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\\n   -2.2927  -13.6779    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n   -3.0023  -12.4356    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\\n   -3.7164  -12.0223    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n   -3.7228  -11.1938    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    0.5619  -12.0133    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\\n    0.5547  -11.1849    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    1.9878  -13.6660    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\\n    1.9863  -14.4910    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    1.2711  -14.9021    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\\n    2.7000  -14.9047    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0\\n   -3.0004   -8.2941    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0\\n   -3.7158   -8.7049    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n   -4.4293   -8.2907    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n   -5.1447   -8.7016    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n 19 21  2  0\\n  4  5  1  0\\n 19 22  1  0\\n  3 11  1  0\\n 21 23  1  0\\n  5  6  1  0\\n 23 24  2  0\\n 11 12  2  0\\n 24 25  1  0\\n  1 16  1  0\\n 25 26  1  0\\n 12 13  1  0\\n  9 27  1  0\\n  2  4  1  0\\n  6 28  1  6\\n 13 14  2  0\\n  7 29  1  6\\n  3 16  1  0\\n  5 30  1  1\\n 13 15  1  0\\n 30 31  1  0\\n  1  2  1  0\\n  2 32  1  6\\n 15 16  2  0\\n 25 33  1  1\\n  6  7  1  0\\n 33 34  1  0\\n 11 17  1  0\\n 26 35  1  1\\n  7  8  1  0\\n 35 36  1  0\\n 17 18  1  0\\n 36 37  2  0\\n  8  9  2  0\\n 36 38  1  0\\n  9 26  1  0\\n 18 19  1  0\\n 15 39  1  0\\n 39 40  1  0\\n 18 20  2  0\\n 40 41  1  0\\n  3 10  2  0\\n 41 42  2  0\\nM  END\\n> <chembl_id>\\nCHEMBL109480\\n\\n> <chembl_pref_name>\\nTANESPIMYCIN\",\n        \"standard_inchi\": \"InChI=1S/C31H43N3O8/c1-8-12-33-26-21-13-17(2)14-25(41-7)27(36)19(4)15-20(5)29(42-31(32)39)24(40-6)11-9-10-18(3)30(38)34-22(28(21)37)16-23(26)35/h8-11,15-17,19,24-25,27,29,33,36H,1,12-14H2,2-7H3,(H2,32,39)(H,34,38)/b11-9-,18-10+,20-15+/t17-,19+,24+,25+,27-,29+/m1/s1\",\n        \"standard_inchi_key\": \"AYUNIORJHRXIBJ-TXHRRWQRSA-N\"\n      },\n      \"molecule_synonyms\": [\n        {\n          \"molecule_synonym\": \"17-AAG\",\n          \"syn_type\": \"RESEARCH_CODE\",\n          \"synonyms\": \"17-AAG\"\n        },\n        {\n          \"molecule_synonym\": \"17aag\",\n          \"syn_type\": \"OTHER\",\n          \"synonyms\": \"17AAG\"\n        },\n        {\n          \"molecule_synonym\": \"BMS-722782\",\n          \"syn_type\": \"RESEARCH_CODE\",\n          \"synonyms\": \"BMS-722782\"\n        },\n        {\n          \"molecule_synonym\": \"CNF-1010\",\n          \"syn_type\": \"RESEARCH_CODE\",\n          \"synonyms\": \"CNF-1010\"\n        },\n        {\n          \"molecule_synonym\": \"CNF1010\",\n          \"syn_type\": \"RESEARCH_CODE\",\n          \"synonyms\": \"CNF1010\"\n        },\n        {\n          \"molecule_synonym\": \"KOS-953\",\n          \"syn_type\": \"RESEARCH_CODE\",\n          \"synonyms\": \"KOS-953\"\n        },\n        {\n          \"molecule_synonym\": \"NSC-330507\",\n          \"syn_type\": \"RESEARCH_CODE\",\n          \"synonyms\": \"NSC-330507\"\n        },\n        {\n          \"molecule_synonym\": \"Tanespimicina\",\n          \"syn_type\": \"INN_SPANISH\",\n          \"synonyms\": \"TANESPIMICINA\"\n        },\n        {\n          \"molecule_synonym\": \"Tanespimycin\",\n          \"syn_type\": \"INN\",\n          \"synonyms\": \"TANESPIMYCIN\"\n        },\n        {\n          \"molecule_synonym\": \"Tanespimycin\",\n          \"syn_type\": \"OTHER\",\n          \"synonyms\": \"TANESPIMYCIN\"\n        },\n        {\n          \"molecule_synonym\": \"Tanespimycin\",\n          \"syn_type\": \"USAN\",\n          \"synonyms\": \"TANESPIMYCIN\"\n        },\n        {\n          \"molecule_synonym\": \"Tanespimycine\",\n          \"syn_type\": \"INN_FRENCH\",\n          \"synonyms\": \"TANESPIMYCINE\"\n        }\n      ],\n      \"molecule_type\": \"Small molecule\",\n      \"natural_product\": 1,\n      \"oral\": false,\n      \"orphan\": 0,\n      \"parenteral\": false,\n      \"polymer_flag\": 0,\n      \"pref_name\": \"TANESPIMYCIN\",\n      \"prodrug\": 0,\n      \"score\": 17.0,\n      \"structure_type\": \"MOL\",\n      \"therapeutic_flag\": false,\n      \"topical\": false,\n      \"usan_stem\": \"-mycin\",\n      \"usan_stem_definition\": \"antibiotics (Streptomyces strain)\",\n      \"usan_substem\": \"-mycin\",\n      \"usan_year\": 2006,\n      \"withdrawn_flag\": false\n    }\n  ],\n  \"page_meta\": {\n    \"limit\": 10,\n    \"next\": null,\n    \"offset\": 0,\n    \"previous\": null,\n    \"total_count\": 2\n  }\n}",
            "thought_1": "The search for \"tanespimycin\" in ChEMBL returned two molecules. CHEMBL109480 has a `pref_name` of \"TANESPIMYCIN\" and a `max_phase` of \"3.0\", indicating it's a more relevant and well-characterized compound. I will use this ChEMBL ID to get its bioactivities. I will specifically look for activities related to cardiac fibrosis. Since \"cardiac fibrosis\" is a complex biological process, I will start by looking for any bioactivities and then refine my search if needed.",
            "tool_name_1": "CHEMBL__get_compound_bioactivities",
            "tool_args_1": {
              "request": {
                "chembl_id": "CHEMBL109480"
              }
            },
            "observation_1": "{\n  \"activities\": [\n    {\n      \"action_type\": null,\n      \"activity_comment\": null,\n      \"activity_id\": 139041,\n      \"activity_properties\": [],\n      \"assay_chembl_id\": \"CHEMBL636772\",\n      \"assay_description\": \"Inhibition of ATP-ase activity in human colon tumor cell line (HCT116)\",\n      \"assay_type\": \"B\",\n      \"assay_variant_accession\": null,\n      \"assay_variant_mutation\": null,\n      \"bao_endpoint\": \"BAO_0000190\",\n      \"bao_format\": \"BAO_0000019\",\n      \"bao_label\": \"assay format\",\n      \"canonical_smiles\": \"C=CCNC1=C2C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\\\\C)[C@H](OC(N)=O)[C@@H](OC)/C=C\\\\C=C(/C)C(=O)NC(=CC1=O)C2=O\",\n      \"data_validity_comment\": null,\n      \"data_validity_description\": null,\n      \"document_chembl_id\": \"CHEMBL1146822\",\n      \"document_journal\": \"Bioorg Med Chem Lett\",\n      \"document_year\": 2004,\n      \"ligand_efficiency\": {\n        \"bei\": \"8.32\",\n        \"le\": \"0.16\",\n        \"lle\": \"2.33\",\n        \"sei\": \"2.93\"\n      },\n      \"molecule_chembl_id\": \"CHEMBL109480\",\n      \"molecule_pref_name\": \"TANESPIMYCIN\",\n      \"parent_molecule_chembl_id\": \"CHEMBL109480\",\n      \"pchembl_value\": \"4.87\",\n      \"potential_duplicate\": 0,\n      \"qudt_units\": \"http://www.openphacts.org/units/Nanomolar\",\n      \"record_id\": 209614,\n      \"relation\": \"=\",\n      \"src_id\": 1,\n      \"standard_flag\": 1,\n      \"standard_relation\": \"=\",\n      \"standard_text_value\": null,\n      \"standard_type\": \"IC50\",\n      \"standard_units\": \"nM\",\n      \"standard_upper_value\": null,\n      \"standard_value\": \"13400.0\",\n      \"target_chembl_id\": \"CHEMBL2095165\",\n      \"target_organism\": \"Homo sapiens\",\n      \"target_pref_name\": \"Heat shock protein HSP90\",\n      \"target_tax_id\": \"9606\",\n      \"text_value\": null,\n      \"toid\": null,\n      \"type\": \"IC50\",\n      \"units\": \"uM\",\n      \"uo_units\": \"UO_0000065\",\n      \"upper_value\": null,\n      \"value\": \"13.4\"\n    },\n    {\n      \"action_type\": null,\n      \"activity_comment\": null,\n      \"activity_id\": 252133,\n      \"activity_properties\": [],\n      \"assay_chembl_id\": \"CHEMBL806580\",\n      \"assay_description\": \"In vitro inhibition of phospho-p185erbB-2 expression in human breast cancer cells(SK-BR-3 cells) at 100 mg/kg dose.\",\n      \"assay_type\": \"F\",\n      \"assay_variant_accession\": null,\n      \"assay_variant_mutation\": null,\n      \"bao_endpoint\": \"BAO_0000201\",\n      \"bao_format\": \"BAO_0000218\",\n      \"bao_label\": \"organism-based format\",\n      \"canonical_smiles\": \"C=CCNC1=C2C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\\\\C)[C@H](OC(N)=O)[C@@H](OC)/C=C\\\\C=C(/C)C(=O)NC(=CC1=O)C2=O\",\n      \"data_validity_comment\": null,\n      \"data_validity_description\": null,\n      \"document_chembl_id\": \"CHEMBL1128559\",\n      \"document_journal\": \"J Med Chem\",\n      \"document_year\": 1995,\n      \"ligand_efficiency\": null,\n      \"molecule_chembl_id\": \"CHEMBL109480\",\n      \"molecule_pref_name\": \"TANESPIMYCIN\",\n      \"parent_molecule_chembl_id\": \"CHEMBL109480\",\n      \"pchembl_value\": null,\n      \"potential_duplicate\": 0,\n      \"qudt_units\": \"http://qudt.org/vocab/unit#Percent\",\n      \"record_id\": 238432,\n      \"relation\": \"=\",\n      \"src_id\": 1,\n      \"standard_flag\": 1,\n      \"standard_relation\": \"=\",\n      \"standard_text_value\": null,\n      \"standard_type\": \"Inhibition\",\n      \"standard_units\": \"%\",\n      \"standard_upper_value\": null,\n      \"standard_value\": \"55.0\",\n      \"target_chembl_id\": \"CHEMBL613834\",\n      \"target_organism\": \"Homo sapiens\",\n      \"target_pref_name\": \"SK-BR-3\",\n      \"target_tax_id\": \"9606\",\n      \"text_value\": null,\n      \"toid\": null,\n      \"type\": \"Inhibition\",\n      \"units\": \"%\",\n      \"uo_units\": \"UO_0000187\",\n      \"upper_value\": null,\n      \"value\": \"55.0\"\n    },\n    {\n      \"action_type\": null,\n      \"activity_comment\": null,\n      \"activity_id\": 252134,\n      \"activity_properties\": [],\n      \"assay_chembl_id\": \"CHEMBL806583\",\n      \"assay_description\": \"In vitro inhibition of phospho-p185erbB-2 expression in human breast cancer cells(SK-BR-3 cells) at 200 mg/kg dose.\",\n      \"assay_type\": \"F\",\n      \"assay_variant_accession\": null,\n      \"assay_variant_mutation\": null,\n      \"bao_endpoint\": \"BAO_0000201\",\n      \"bao_format\": \"BAO_0000218\",\n      \"bao_label\": \"organism-based format\",\n      \"canonical_smiles\": \"C=CCNC1=C2C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\\\\C)[C@H](OC(N)=O)[C@@H](OC)/C=C\\\\C=C(/C)C(=O)NC(=CC1=O)C2=O\",\n      \"data_validity_comment\": null,\n      \"data_validity_description\": null,\n      \"document_chembl_id\": \"CHEMBL1128559\",\n      \"document_journal\": \"J Med Chem\",\n      \"document_year\": 1995,\n      \"ligand_efficiency\": null,\n      \"molecule_chembl_id\": \"CHEMBL109480\",\n      \"molecule_pref_name\": \"TANESPIMYCIN\",\n      \"parent_molecule_chembl_id\": \"CHEMBL109480\",\n      \"pchembl_value\": null,\n      \"potential_duplicate\": 0,\n      \"qudt_units\": \"http://qudt.org/vocab/unit#Percent\",\n      \"record_id\": 238432,\n      \"relation\": \"=\",\n      \"src_id\": 1,\n      \"standard_flag\": 1,\n      \"standard_relation\": \"=\",\n      \"standard_text_value\": null,\n      \"standard_type\": \"Inhibition\",\n      \"standard_units\": \"%\",\n      \"standard_upper_value\": null,\n      \"standard_value\": \"68.0\",\n      \"target_chembl_id\": \"CHEMBL613834\",\n      \"target_organism\": \"Homo sapiens\",\n      \"target_pref_name\": \"SK-BR-3\",\n      \"target_tax_id\": \"9606\",\n      \"text_value\": null,\n      \"toid\": null,\n      \"type\": \"Inhibition\",\n      \"units\": \"%\",\n      \"uo_units\": \"UO_0000187\",\n      \"upper_value\": null,\n      \"value\": \"68.0\"\n    },\n    {\n      \"action_type\": null,\n      \"activity_comment\": null,\n      \"activity_id\": 252135,\n      \"activity_properties\": [],\n      \"assay_chembl_id\": \"CHEMBL806403\",\n      \"assay_description\": \"Inhibition of oncogene product p185 erbB-2 from human breast cancer cells(SK-BR-3 cells) at 50 mg/kg dose.\",\n      \"assay_type\": \"F\",\n      \"assay_variant_accession\": null,\n      \"assay_variant_mutation\": null,\n      \"bao_endpoint\": \"BAO_0000190\",\n      \"bao_format\": \"BAO_0000218\",\n      \"bao_label\": \"organism-based format\",\n      \"canonical_smiles\": \"C=CCNC1=C2C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\\\\C)[C@H](OC(N)=O)[C@@H](OC)/C=C\\\\C=C(/C)C(=O)NC(=CC1=O)C2=O\",\n      \"data_validity_comment\": null,\n      \"data_validity_description\": null,\n      \"document_chembl_id\": \"CHEMBL1128559\",\n      \"document_journal\": \"J Med Chem\",\n      \"document_year\": 1995,\n      \"ligand_efficiency\": null,\n      \"molecule_chembl_id\": \"CHEMBL109480\",\n      \"molecule_pref_name\": \"TANESPIMYCIN\",\n      \"parent_molecule_chembl_id\": \"CHEMBL109480\",\n      \"pchembl_value\": \"7.51\",\n      \"potential_duplicate\": 0,\n      \"qudt_units\": \"http://www.openphacts.org/units/Nanomolar\",\n      \"record_id\": 238432,\n      \"relation\": \"=\",\n      \"src_id\": 1,\n      \"standard_flag\": 1,\n      \"standard_relation\": \"=\",\n      \"standard_text_value\": null,\n      \"standard_type\": \"IC50\",\n      \"standard_units\": \"nM\",\n      \"standard_upper_value\": null,\n      \"standard_value\": \"31.0\",\n      \"target_chembl_id\": \"CHEMBL613834\",\n      \"target_organism\": \"Homo sapiens\",\n      \"target_pref_name\": \"SK-BR-3\",\n      \"target_tax_id\": \"9606\",\n      \"text_value\": null,\n      \"toid\": null,\n      \"type\": \"IC50\",\n      \"units\": \"nM\",\n      \"uo_units\": \"UO_0000065\",\n      \"upper_value\": null,\n      \"value\": \"31.0\"\n    },\n    {\n      \"action_type\": null,\n      \"activity_comment\": null,\n      \"activity_id\": 252136,\n      \"activity_properties\": [],\n      \"assay_chembl_id\": \"CHEMBL719227\",\n      \"assay_description\": \"In vivo inhibition of phospho-p185erbB-2 expression in human SK-BR-3 tumors at 50 mg/kg dose in mice\",\n      \"assay_type\": \"F\",\n      \"assay_variant_accession\": null,\n      \"assay_variant_mutation\": null,\n      \"bao_endpoint\": \"BAO_0000201\",\n      \"bao_format\": \"BAO_0000218\",\n      \"bao_label\": \"organism-based format\",\n      \"canonical_smiles\": \"C=CCNC1=C2C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\\\\C)[C@H](OC(N)=O)[C@@H](OC)/C=C\\\\C=C(/C)C(=O)NC(=CC1=O)C2=O\",\n      \"data_validity_comment\": null,\n      \"data_validity_description\": null,\n      \"document_chembl_id\": \"CHEMBL1128559\",\n      \"document_journal\": \"J Med Chem\",\n      \"document_year\": 1995,\n      \"ligand_efficiency\": null,\n      \"molecule_chembl_id\": \"CHEMBL109480\",\n      \"molecule_pref_name\": \"TANESPIMYCIN\",\n      \"parent_molecule_chembl_id\": \"CHEMBL109480\",\n      \"pchembl_value\": null,\n      \"potential_duplicate\": 0,\n      \"qudt_units\": \"http://qudt.org/vocab/unit#Percent\",\n      \"record_id\": 238432,\n      \"relation\": \"=\",\n      \"src_id\": 1,\n      \"standard_flag\": 1,\n      \"standard_relation\": \"=\",\n      \"standard_text_value\": null,\n      \"standard_type\": \"Inhibition\",\n      \"standard_units\": \"%\",\n      \"standard_upper_value\": null,\n      \"standard_value\": \"27.0\",\n      \"target_chembl_id\": \"CHEMBL375\",\n      \"target_organism\": \"Mus musculus\",\n      \"target_pref_name\": \"Mus musculus\",\n      \"target_tax_id\": \"10090\",\n      \"text_value\": null,\n      \"toid\": null,\n      \"type\": \"Inhibition\",\n      \"units\": \"%\",\n      \"uo_units\": \"UO_0000187\",\n      \"upper_value\": null,\n      \"value\": \"27.0\"\n    },\n    {\n      \"action_type\": null,\n      \"activity_comment\": null,\n      \"activity_id\": 252137,\n      \"activity_properties\": [],\n      \"assay_chembl_id\": \"CHEMBL719301\",\n      \"assay_description\": \"In vivo inhibition of phospho-p185erbB-2 expression in human SK-BR-3 tumors at 100 mg/kg dose in mice\",\n      \"assay_type\": \"F\",\n      \"assay_variant_accession\": null,\n      \"assay_variant_mutation\": null,\n      \"bao_endpoint\": \"BAO_0000201\",\n      \"bao_format\": \"BAO_0000218\",\n      \"bao_label\": \"organism-based format\",\n      \"canonical_smiles\": \"C=CCNC1=C2C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\\\\C)[C@H](OC(N)=O)[C@@H](OC)/C=C\\\\C=C(/C)C(=O)NC(=CC1=O)C2=O\",\n      \"data_validity_comment\": null,\n      \"data_validity_description\": null,\n      \"document_chembl_id\": \"CHEMBL1128559\",\n      \"document_journal\": \"J Med Chem\",\n      \"document_year\": 1995,\n      \"ligand_efficiency\": null,\n      \"molecule_chembl_id\": \"CHEMBL109480\",\n      \"molecule_pref_name\": \"TANESPIMYCIN\",\n      \"parent_molecule_chembl_id\": \"CHEMBL109480\",\n      \"pchembl_value\": null,\n      \"potential_duplicate\": 0,\n      \"qudt_units\": \"http://qudt.org/vocab/unit#Percent\",\n      \"record_id\": 238432,\n      \"relation\": \"=\",\n      \"src_id\": 1,\n      \"standard_flag\": 1,\n      \"standard_relation\": \"=\",\n      \"standard_text_value\": null,\n      \"standard_type\": \"Inhibition\",\n      \"standard_units\": \"%\",\n      \"standard_upper_value\": null,\n      \"standard_value\": \"60.0\",\n      \"target_chembl_id\": \"CHEMBL375\",\n      \"target_organism\": \"Mus musculus\",\n      \"target_pref_name\": \"Mus musculus\",\n      \"target_tax_id\": \"10090\",\n      \"text_value\": null,\n      \"toid\": null,\n      \"type\": \"Inhibition\",\n      \"units\": \"%\",\n      \"uo_units\": \"UO_0000187\",\n      \"upper_value\": null,\n      \"value\": \"60.0\"\n    },\n    {\n      \"action_type\": null,\n      \"activity_comment\": null,\n      \"activity_id\": 252138,\n      \"activity_properties\": [],\n      \"assay_chembl_id\": \"CHEMBL719223\",\n      \"assay_description\": \"In vivo inhibition of phospho-p185erbB-2 expression in human SK-BR-3 tumors at 200 mg/kg dose in mice\",\n      \"assay_type\": \"F\",\n      \"assay_variant_accession\": null,\n      \"assay_variant_mutation\": null,\n      \"bao_endpoint\": \"BAO_0000201\",\n      \"bao_format\": \"BAO_0000218\",\n      \"bao_label\": \"organism-based format\",\n      \"canonical_smiles\": \"C=CCNC1=C2C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\\\\C)[C@H](OC(N)=O)[C@@H](OC)/C=C\\\\C=C(/C)C(=O)NC(=CC1=O)C2=O\",\n      \"data_validity_comment\": null,\n      \"data_validity_description\": null,\n      \"document_chembl_id\": \"CHEMBL1128559\",\n      \"document_journal\": \"J Med Chem\",\n      \"document_year\": 1995,\n      \"ligand_efficiency\": null,\n      \"molecule_chembl_id\": \"CHEMBL109480\",\n      \"molecule_pref_name\": \"TANESPIMYCIN\",\n      \"parent_molecule_chembl_id\": \"CHEMBL109480\",\n      \"pchembl_value\": null,\n      \"potential_duplicate\": 0,\n      \"qudt_units\": \"http://qudt.org/vocab/unit#Percent\",\n      \"record_id\": 238432,\n      \"relation\": \"=\",\n      \"src_id\": 1,\n      \"standard_flag\": 1,\n      \"standard_relation\": \"=\",\n      \"standard_text_value\": null,\n      \"standard_type\": \"Inhibition\",\n      \"standard_units\": \"%\",\n      \"standard_upper_value\": null,\n      \"standard_value\": \"80.0\",\n      \"target_chembl_id\": \"CHEMBL375\",\n      \"target_organism\": \"Mus musculus\",\n      \"target_pref_name\": \"Mus musculus\",\n      \"target_tax_id\": \"10090\",\n      \"text_value\": null,\n      \"toid\": null,\n      \"type\": \"Inhibition\",\n      \"units\": \"%\",\n      \"uo_units\": \"UO_0000187\",\n      \"upper_value\": null,\n      \"value\": \"80.0\"\n    },\n    {\n      \"action_type\": null,\n      \"activity_comment\": null,\n      \"activity_id\": 252139,\n      \"activity_properties\": [],\n      \"assay_chembl_id\": \"CHEMBL719224\",\n      \"assay_description\": \"In vivo inhibition of phospho-p185erbB-2 expression in human SK-BR-3 tumors at 400 mg/kg dose in mice\",\n      \"assay_type\": \"F\",\n      \"assay_variant_accession\": null,\n      \"assay_variant_mutation\": null,\n      \"bao_endpoint\": \"BAO_0000201\",\n      \"bao_format\": \"BAO_0000218\",\n      \"bao_label\": \"organism-based format\",\n      \"canonical_smiles\": \"C=CCNC1=C2C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\\\\C)[C@H](OC(N)=O)[C@@H](OC)/C=C\\\\C=C(/C)C(=O)NC(=CC1=O)C2=O\",\n      \"data_validity_comment\": null,\n      \"data_validity_description\": null,\n      \"document_chembl_id\": \"CHEMBL1128559\",\n      \"document_journal\": \"J Med Chem\",\n      \"document_year\": 1995,\n      \"ligand_efficiency\": null,\n      \"molecule_chembl_id\": \"CHEMBL109480\",\n      \"molecule_pref_name\": \"TANESPIMYCIN\",\n      \"parent_molecule_chembl_id\": \"CHEMBL109480\",\n      \"pchembl_value\": null,\n      \"potential_duplicate\": 0,\n      \"qudt_units\": \"http://qudt.org/vocab/unit#Percent\",\n      \"record_id\": 238432,\n      \"relation\": \"=\",\n      \"src_id\": 1,\n      \"standard_flag\": 1,\n      \"standard_relation\": \"=\",\n      \"standard_text_value\": null,\n      \"standard_type\": \"Inhibition\",\n      \"standard_units\": \"%\",\n      \"standard_upper_value\": null,\n      \"standard_value\": \"72.0\",\n      \"target_chembl_id\": \"CHEMBL375\",\n      \"target_organism\": \"Mus musculus\",\n      \"target_pref_name\": \"Mus musculus\",\n      \"target_tax_id\": \"10090\",\n      \"text_value\": null,\n      \"toid\": null,\n      \"type\": \"Inhibition\",\n      \"units\": \"%\",\n      \"uo_units\": \"UO_0000187\",\n      \"upper_value\": null,\n      \"value\": \"72.0\"\n    },\n    {\n      \"action_type\": null,\n      \"activity_comment\": null,\n      \"activity_id\": 478780,\n      \"activity_properties\": [],\n      \"assay_chembl_id\": \"CHEMBL760293\",\n      \"assay_description\": \"Inhibition of Phoshoinositol 3 kinase from MCF-7 breast cancer cells\",\n      \"assay_type\": \"B\",\n      \"assay_variant_accession\": null,\n      \"assay_variant_mutation\": null,\n      \"bao_endpoint\": \"BAO_0000190\",\n      \"bao_format\": \"BAO_0000219\",\n      \"bao_label\": \"cell-based format\",\n      \"canonical_smiles\": \"C=CCNC1=C2C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\\\\C)[C@H](OC(N)=O)[C@@H](OC)/C=C\\\\C=C(/C)C(=O)NC(=CC1=O)C2=O\",\n      \"data_validity_comment\": \"Outside typical range\",\n      \"data_validity_description\": \"Values for this activity type are unusually large/small, so may not be accurate\",\n      \"document_chembl_id\": \"CHEMBL1134011\",\n      \"document_journal\": \"Bioorg Med Chem Lett\",\n      \"document_year\": 2001,\n      \"ligand_efficiency\": null,\n      \"molecule_chembl_id\": \"CHEMBL109480\",\n      \"molecule_pref_name\": \"TANESPIMYCIN\",\n      \"parent_molecule_chembl_id\": \"CHEMBL109480\",\n      \"pchembl_value\": null,\n      \"potential_duplicate\": 0,\n      \"qudt_units\": \"http://www.openphacts.org/units/Nanomolar\",\n      \"record_id\": 340189,\n      \"relation\": \">\",\n      \"src_id\": 1,\n      \"standard_flag\": 1,\n      \"standard_relation\": \">\",\n      \"standard_text_value\": null,\n      \"standard_type\": \"IC50\",\n      \"standard_units\": \"nM\",\n      \"standard_upper_value\": null,\n      \"standard_value\": \"500000.0\",\n      \"target_chembl_id\": \"CHEMBL612545\",\n      \"target_organism\": null,\n      \"target_pref_name\": \"Unchecked\",\n      \"target_tax_id\": null,\n      \"text_value\": null,\n      \"toid\": null,\n      \"type\": \"IC50\",\n      \"units\": \"uM\",\n      \"uo_units\": \"UO_0000065\",\n      \"upper_value\": null,\n      \"value\": \"500.0\"\n    },\n    {\n      \"action_type\": null,\n      \"activity_comment\": null,\n      \"activity_id\": 478781,\n      \"activity_properties\": [],\n      \"assay_chembl_id\": \"CHEMBL662174\",\n      \"assay_description\": \"Inhibition of DNA dependent protein kinase activity without hsp90 alpha protein\",\n      \"assay_type\": \"B\",\n      \"assay_variant_accession\": null,\n      \"assay_variant_mutation\": null,\n      \"bao_endpoint\": \"BAO_0000190\",\n      \"bao_format\": \"BAO_0000357\",\n      \"bao_label\": \"single protein format\",\n      \"canonical_smiles\": \"C=CCNC1=C2C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\\\\C)[C@H](OC(N)=O)[C@@H](OC)/C=C\\\\C=C(/C)C(=O)NC(=CC1=O)C2=O\",\n      \"data_validity_comment\": null,\n      \"data_validity_description\": null,\n      \"document_chembl_id\": \"CHEMBL1134011\",\n      \"document_journal\": \"Bioorg Med Chem Lett\",\n      \"document_year\": 2001,\n      \"ligand_efficiency\": null,\n      \"molecule_chembl_id\": \"CHEMBL109480\",\n      \"molecule_pref_name\": \"TANESPIMYCIN\",\n      \"parent_molecule_chembl_id\": \"CHEMBL109480\",\n      \"pchembl_value\": null,\n      \"potential_duplicate\": 0,\n      \"qudt_units\": \"http://www.openphacts.org/units/Nanomolar\",\n      \"record_id\": 340189,\n      \"relation\": \">\",\n      \"src_id\": 1,\n      \"standard_flag\": 1,\n      \"standard_relation\": \">\",\n      \"standard_text_value\": null,\n      \"standard_type\": \"IC50\",\n      \"standard_units\": \"nM\",\n      \"standard_upper_value\": null,\n      \"standard_value\": \"40000.0\",\n      \"target_chembl_id\": \"CHEMBL3142\",\n      \"target_organism\": \"Homo sapiens\",\n      \"target_pref_name\": \"DNA-dependent protein kinase\",\n      \"target_tax_id\": \"9606\",\n      \"text_value\": null,\n      \"toid\": null,\n      \"type\": \"IC50\",\n      \"units\": \"uM\",\n      \"uo_units\": \"UO_0000065\",\n      \"upper_value\": null,\n      \"value\": \"40.0\"\n    }\n  ],\n  \"page_meta\": {\n    \"limit\": 10,\n    \"next\": \"/chembl/api/data/activity.json?limit=10&offset=10&molecule_chembl_id=CHEMBL109480\",\n    \"offset\": 0,\n    \"previous\": null,\n    \"total_count\": 1111\n  }\n}",
            "thought_2": "The bioactivities for tanespimycin (CHEMBL109480) show various inhibitions, primarily related to cancer cell lines and proteins like Heat shock protein HSP90, phospho-p185erbB-2, Phoshoinositol 3 kinase, and DNA-dependent protein kinase. While these are important for its known anticancer properties, none of the descriptions directly mention \"cardiac fibrosis\" or related terms.\n\nTo assess efficacy for cardiac fibrosis, I need to look for more specific information. I will first check if tanespimycin is a known drug and if it has any indications related to cardiovascular diseases or fibrosis. If not, I will broaden my search to PubMed to find any research linking tanespimycin to cardiac fibrosis.",
            "tool_name_2": "CHEMBL__get_drug_info",
            "tool_args_2": {
              "request": {
                "chembl_id": "CHEMBL109480"
              }
            },
            "observation_2": "{\n  \"drugs\": [\n    {\n      \"applicants\": null,\n      \"atc_code_description\": null,\n      \"availability_type\": null,\n      \"biotherapeutic\": null,\n      \"black_box\": 0,\n      \"black_box_warning\": \"0\",\n      \"chirality\": 1,\n      \"drug_type\": 1,\n      \"first_approval\": null,\n      \"first_in_class\": 0,\n      \"helm_notation\": null,\n      \"indication_class\": null,\n      \"max_phase\": \"3.0\",\n      \"molecule_chembl_id\": \"CHEMBL109480\",\n      \"molecule_properties\": {\n        \"alogp\": \"2.54\",\n        \"aromatic_rings\": 0,\n        \"cx_logd\": \"2.57\",\n        \"cx_logp\": \"2.57\",\n        \"cx_most_apka\": \"12.78\",\n        \"cx_most_bpka\": null,\n        \"full_molformula\": \"C31H43N3O8\",\n        \"full_mwt\": \"585.70\",\n        \"hba\": 9,\n        \"hba_lipinski\": 11,\n        \"hbd\": 4,\n        \"hbd_lipinski\": 5,\n        \"heavy_atoms\": 42,\n        \"molecular_species\": \"NEUTRAL\",\n        \"mw_freebase\": \"585.70\",\n        \"mw_monoisotopic\": \"585.3050\",\n        \"np_likeness_score\": \"2.38\",\n        \"num_lipinski_ro5_violations\": 2,\n        \"num_ro5_violations\": 1,\n        \"psa\": \"166.28\",\n        \"qed_weighted\": \"0.27\",\n        \"ro3_pass\": \"N\",\n        \"rtb\": 6\n      },\n      \"molecule_structures\": {\n        \"canonical_smiles\": \"C=CCNC1=C2C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\\\\C)[C@H](OC(N)=O)[C@@H](OC)/C=C\\\\C=C(/C)C(=O)NC(=CC1=O)C2=O\",\n        \"molfile\": \"\\n     RDKit          2D\\n\\n 42 43  0  0  0  0  0  0  0  0999 V2000\\n   -3.0155   -9.9521    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n   -3.0107  -10.7771    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n   -1.5752   -9.9474    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n   -2.2856  -11.1902    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n   -2.2875  -12.0239    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n   -1.5769  -12.4343    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n   -1.5771  -13.2676    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n   -0.8673  -13.6831    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n   -0.1346  -13.2613    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n   -1.5772  -10.7724    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\\n   -0.8598   -9.5365    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n   -0.8579   -8.7115    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n   -1.5714   -8.2974    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n   -1.5695   -7.4724    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\\n   -2.2868   -8.7082    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n   -2.2887   -9.5332    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n   -0.1463   -9.9507    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0\\n    0.5691   -9.5398    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    1.2802   -9.9521    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    0.5709   -8.7148    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\\n    1.2787  -10.7771    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    1.9954   -9.5410    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    1.9924  -11.1910    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    1.9908  -12.0160    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    1.2756  -12.4271    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    1.2741  -13.2521    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n   -0.1335  -12.4363    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n   -0.8677  -12.0146    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\\n   -2.2927  -13.6779    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n   -3.0023  -12.4356    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\\n   -3.7164  -12.0223    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n   -3.7228  -11.1938    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    0.5619  -12.0133    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\\n    0.5547  -11.1849    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    1.9878  -13.6660    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\\n    1.9863  -14.4910    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    1.2711  -14.9021    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\\n    2.7000  -14.9047    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0\\n   -3.0004   -8.2941    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0\\n   -3.7158   -8.7049    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n   -4.4293   -8.2907    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n   -5.1447   -8.7016    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n 19 21  2  0\\n  4  5  1  0\\n 19 22  1  0\\n  3 11  1  0\\n 21 23  1  0\\n  5  6  1  0\\n 23 24  2  0\\n 11 12  2  0\\n 24 25  1  0\\n  1 16  1  0\\n 25 26  1  0\\n 12 13  1  0\\n  9 27  1  0\\n  2  4  1  0\\n  6 28  1  6\\n 13 14  2  0\\n  7 29  1  6\\n  3 16  1  0\\n  5 30  1  1\\n 13 15  1  0\\n 30 31  1  0\\n  1  2  1  0\\n  2 32  1  6\\n 15 16  2  0\\n 25 33  1  1\\n  6  7  1  0\\n 33 34  1  0\\n 11 17  1  0\\n 26 35  1  1\\n  7  8  1  0\\n 35 36  1  0\\n 17 18  1  0\\n 36 37  2  0\\n  8  9  2  0\\n 36 38  1  0\\n  9 26  1  0\\n 18 19  1  0\\n 15 39  1  0\\n 39 40  1  0\\n 18 20  2  0\\n 40 41  1  0\\n  3 10  2  0\\n 41 42  2  0\\nM  END\\n\",\n        \"standard_inchi\": \"InChI=1S/C31H43N3O8/c1-8-12-33-26-21-13-17(2)14-25(41-7)27(36)19(4)15-20(5)29(42-31(32)39)24(40-6)11-9-10-18(3)30(38)34-22(28(21)37)16-23(26)35/h8-11,15-17,19,24-25,27,29,33,36H,1,12-14H2,2-7H3,(H2,32,39)(H,34,38)/b11-9-,18-10+,20-15+/t17-,19+,24+,25+,27-,29+/m1/s1\",\n        \"standard_inchi_key\": \"AYUNIORJHRXIBJ-TXHRRWQRSA-N\"\n      },\n      \"molecule_synonyms\": [\n        {\n          \"molecule_synonym\": \"17-AAG\",\n          \"syn_type\": \"RESEARCH_CODE\",\n          \"synonyms\": \"17-AAG\"\n        },\n        {\n          \"molecule_synonym\": \"17aag\",\n          \"syn_type\": \"OTHER\",\n          \"synonyms\": \"17AAG\"\n        },\n        {\n          \"molecule_synonym\": \"BMS-722782\",\n          \"syn_type\": \"RESEARCH_CODE\",\n          \"synonyms\": \"BMS-722782\"\n        },\n        {\n          \"molecule_synonym\": \"CNF-1010\",\n          \"syn_type\": \"RESEARCH_CODE\",\n          \"synonyms\": \"CNF-1010\"\n        },\n        {\n          \"molecule_synonym\": \"CNF1010\",\n          \"syn_type\": \"RESEARCH_CODE\",\n          \"synonyms\": \"CNF1010\"\n        },\n        {\n          \"molecule_synonym\": \"KOS-953\",\n          \"syn_type\": \"RESEARCH_CODE\",\n          \"synonyms\": \"KOS-953\"\n        },\n        {\n          \"molecule_synonym\": \"NSC-330507\",\n          \"syn_type\": \"RESEARCH_CODE\",\n          \"synonyms\": \"NSC-330507\"\n        },\n        {\n          \"molecule_synonym\": \"Tanespimicina\",\n          \"syn_type\": \"INN_SPANISH\",\n          \"synonyms\": \"TANESPIMICINA\"\n        },\n        {\n          \"molecule_synonym\": \"Tanespimycin\",\n          \"syn_type\": \"INN\",\n          \"synonyms\": \"TANESPIMYCIN\"\n        },\n        {\n          \"molecule_synonym\": \"Tanespimycin\",\n          \"syn_type\": \"OTHER\",\n          \"synonyms\": \"TANESPIMYCIN\"\n        },\n        {\n          \"molecule_synonym\": \"Tanespimycin\",\n          \"syn_type\": \"USAN\",\n          \"synonyms\": \"TANESPIMYCIN\"\n        },\n        {\n          \"molecule_synonym\": \"Tanespimycine\",\n          \"syn_type\": \"INN_FRENCH\",\n          \"synonyms\": \"TANESPIMYCINE\"\n        }\n      ],\n      \"ob_patent\": null,\n      \"oral\": 0,\n      \"parenteral\": 0,\n      \"prodrug\": 0,\n      \"research_codes\": [\n        \"NSC-330507\",\n        \"17-AAG\",\n        \"BMS-722782\",\n        \"CNF-1010\",\n        \"CNF1010\",\n        \"KOS-953\"\n      ],\n      \"rule_of_five\": 0,\n      \"sc_patent\": null,\n      \"synonyms\": [\n        \"Tanespimycin (INN, USAN)\",\n        \"\"\n      ],\n      \"topical\": 0,\n      \"usan_stem\": \"-mycin\",\n      \"usan_stem_definition\": \"antibiotics (Streptomyces strain)\",\n      \"usan_stem_substem\": \"-mycin(-mycin)\",\n      \"usan_year\": 2006,\n      \"withdrawn_flag\": \"0\"\n    }\n  ],\n  \"page_meta\": {\n    \"limit\": 10,\n    \"next\": null,\n    \"offset\": 0,\n    \"previous\": null,\n    \"total_count\": 1\n  }\n}",
            "thought_3": "I have confirmed that Tanespimycin (CHEMBL109480) is a drug in Phase 3 development, but the `get_drug_info` output does not provide specific indications. The previous `get_compound_bioactivities` call also did not show any direct links to cardiac fibrosis.\n\nTherefore, the next logical step is to check for drug indications using the `CHEMBL__get_drug_indications` tool. This will tell me if it's being developed for any cardiovascular conditions or fibrosis. If no relevant indications are found, I will then proceed to search PubMed abstracts for any scientific literature connecting tanespimycin to cardiac fibrosis.",
            "tool_name_3": "CHEMBL__get_drug_indications",
            "tool_args_3": {
              "request": {
                "chembl_id": "CHEMBL109480"
              }
            },
            "observation_3": "{\n  \"drug_indications\": [\n    {\n      \"drugind_id\": 54956,\n      \"efo_id\": \"EFO:0000673\",\n      \"efo_term\": \"prostate adenocarcinoma\",\n      \"indication_refs\": [\n        {\n          \"ref_id\": \"NCT00118092\",\n          \"ref_type\": \"ClinicalTrials\",\n          \"ref_url\": \"https://clinicaltrials.gov/search?term=NCT00118092\"\n        }\n      ],\n      \"max_phase_for_ind\": \"2.0\",\n      \"mesh_heading\": \"Prostatic Neoplasms\",\n      \"mesh_id\": \"D011471\",\n      \"molecule_chembl_id\": \"CHEMBL109480\",\n      \"parent_molecule_chembl_id\": \"CHEMBL109480\"\n    },\n    {\n      \"drugind_id\": 54973,\n      \"efo_id\": \"EFO:0000756\",\n      \"efo_term\": \"melanoma\",\n      \"indication_refs\": [\n        {\n          \"ref_id\": \"NCT00087386\",\n          \"ref_type\": \"ClinicalTrials\",\n          \"ref_url\": \"https://clinicaltrials.gov/search?term=NCT00087386\"\n        }\n      ],\n      \"max_phase_for_ind\": \"2.0\",\n      \"mesh_heading\": \"Melanoma\",\n      \"mesh_id\": \"D008545\",\n      \"molecule_chembl_id\": \"CHEMBL109480\",\n      \"parent_molecule_chembl_id\": \"CHEMBL109480\"\n    },\n    {\n      \"drugind_id\": 65983,\n      \"efo_id\": \"EFO:0000095\",\n      \"efo_term\": \"chronic lymphocytic leukemia\",\n      \"indication_refs\": [\n        {\n          \"ref_id\": \"NCT00004241,NCT00096005,NCT00098488,NCT00319930\",\n          \"ref_type\": \"ClinicalTrials\",\n          \"ref_url\": \"https://clinicaltrials.gov/search?term=NCT00004241%20NCT00096005%20NCT00098488%20NCT00319930\"\n        }\n      ],\n      \"max_phase_for_ind\": \"1.0\",\n      \"mesh_heading\": \"Leukemia, Lymphocytic, Chronic, B-Cell\",\n      \"mesh_id\": \"D015451\",\n      \"molecule_chembl_id\": \"CHEMBL109480\",\n      \"parent_molecule_chembl_id\": \"CHEMBL109480\"\n    },\n    {\n      \"drugind_id\": 65984,\n      \"efo_id\": \"EFO:0000183\",\n      \"efo_term\": \"Hodgkins lymphoma\",\n      \"indication_refs\": [\n        {\n          \"ref_id\": \"NCT00004241,NCT00096005,NCT00117988\",\n          \"ref_type\": \"ClinicalTrials\",\n          \"ref_url\": \"https://clinicaltrials.gov/search?term=NCT00004241%20NCT00096005%20NCT00117988\"\n        }\n      ],\n      \"max_phase_for_ind\": \"2.0\",\n      \"mesh_heading\": \"Hodgkin Disease\",\n      \"mesh_id\": \"D006689\",\n      \"molecule_chembl_id\": \"CHEMBL109480\",\n      \"parent_molecule_chembl_id\": \"CHEMBL109480\"\n    },\n    {\n      \"drugind_id\": 65985,\n      \"efo_id\": \"EFO:0000389\",\n      \"efo_term\": \"cutaneous melanoma\",\n      \"indication_refs\": [\n        {\n          \"ref_id\": \"NCT00004065,NCT00104897\",\n          \"ref_type\": \"ClinicalTrials\",\n          \"ref_url\": \"https://clinicaltrials.gov/search?term=NCT00004065%20NCT00104897\"\n        }\n      ],\n      \"max_phase_for_ind\": \"2.0\",\n      \"mesh_heading\": \"Melanoma\",\n      \"mesh_id\": \"D008545\",\n      \"molecule_chembl_id\": \"CHEMBL109480\",\n      \"parent_molecule_chembl_id\": \"CHEMBL109480\"\n    },\n    {\n      \"drugind_id\": 65986,\n      \"efo_id\": \"EFO:0000565\",\n      \"efo_term\": \"leukemia\",\n      \"indication_refs\": [\n        {\n          \"ref_id\": \"NCT00004065,NCT00066326,NCT00100997,NCT00132015\",\n          \"ref_type\": \"ClinicalTrials\",\n          \"ref_url\": \"https://clinicaltrials.gov/search?term=NCT00004065%20NCT00066326%20NCT00100997%20NCT00132015\"\n        }\n      ],\n      \"max_phase_for_ind\": \"2.0\",\n      \"mesh_heading\": \"Leukemia\",\n      \"mesh_id\": \"D007938\",\n      \"molecule_chembl_id\": \"CHEMBL109480\",\n      \"parent_molecule_chembl_id\": \"CHEMBL109480\"\n    },\n    {\n      \"drugind_id\": 65987,\n      \"efo_id\": \"EFO:0000574\",\n      \"efo_term\": \"lymphoma\",\n      \"indication_refs\": [\n        {\n          \"ref_id\": \"NCT00004075,NCT00132015\",\n          \"ref_type\": \"ClinicalTrials\",\n          \"ref_url\": \"https://clinicaltrials.gov/search?term=NCT00004075%20NCT00132015\"\n        }\n      ],\n      \"max_phase_for_ind\": \"2.0\",\n      \"mesh_heading\": \"Lymphoma\",\n      \"mesh_id\": \"D008223\",\n      \"molecule_chembl_id\": \"CHEMBL109480\",\n      \"parent_molecule_chembl_id\": \"CHEMBL109480\"\n    },\n    {\n      \"drugind_id\": 65988,\n      \"efo_id\": \"EFO:0000616\",\n      \"efo_term\": \"neoplasm\",\n      \"indication_refs\": [\n        {\n          \"ref_id\": \"NCT00003969,NCT00047047,NCT00087217,NCT00119236,NCT00121264\",\n          \"ref_type\": \"ClinicalTrials\",\n          \"ref_url\": \"https://clinicaltrials.gov/search?term=NCT00003969%20NCT00047047%20NCT00087217%20NCT00119236%20NCT00121264\"\n        }\n      ],\n      \"max_phase_for_ind\": \"2.0\",\n      \"mesh_heading\": \"Neoplasms\",\n      \"mesh_id\": \"D009369\",\n      \"molecule_chembl_id\": \"CHEMBL109480\",\n      \"parent_molecule_chembl_id\": \"CHEMBL109480\"\n    },\n    {\n      \"drugind_id\": 65989,\n      \"efo_id\": \"EFO:0001378\",\n      \"efo_term\": \"multiple myeloma\",\n      \"indication_refs\": [\n        {\n          \"ref_id\": \"NCT00514371,NCT00546780\",\n          \"ref_type\": \"ClinicalTrials\",\n          \"ref_url\": \"https://clinicaltrials.gov/search?term=NCT00514371%20NCT00546780\"\n        }\n      ],\n      \"max_phase_for_ind\": \"3.0\",\n      \"mesh_heading\": \"Multiple Myeloma\",\n      \"mesh_id\": \"D009101\",\n      \"molecule_chembl_id\": \"CHEMBL109480\",\n      \"parent_molecule_chembl_id\": \"CHEMBL109480\"\n    },\n    {\n      \"drugind_id\": 65992,\n      \"efo_id\": \"EFO:0003032\",\n      \"efo_term\": \"anaplastic large cell lymphoma\",\n      \"indication_refs\": [\n        {\n          \"ref_id\": \"NCT00004241,NCT00096005,NCT00117988\",\n          \"ref_type\": \"ClinicalTrials\",\n          \"ref_url\": \"https://clinicaltrials.gov/search?term=NCT00004241%20NCT00096005%20NCT00117988\"\n        }\n      ],\n      \"max_phase_for_ind\": \"2.0\",\n      \"mesh_heading\": \"Lymphoma, Large-Cell, Anaplastic\",\n      \"mesh_id\": \"D017728\",\n      \"molecule_chembl_id\": \"CHEMBL109480\",\n      \"parent_molecule_chembl_id\": \"CHEMBL109480\"\n    }\n  ],\n  \"page_meta\": {\n    \"limit\": 10,\n    \"next\": \"/chembl/api/data/drug_indication.json?limit=10&offset=10&molecule_chembl_id=CHEMBL109480\",\n    \"offset\": 0,\n    \"previous\": null,\n    \"total_count\": 38\n  }\n}",
            "thought_4": "The `CHEMBL__get_drug_indications` tool shows that Tanespimycin is primarily indicated for various cancers (prostate adenocarcinoma, melanoma, leukemia, lymphoma, multiple myeloma). There are no indications related to cardiac fibrosis or any other cardiovascular conditions.\n\nSince ChEMBL did not provide direct evidence of tanespimycin's efficacy in cardiac fibrosis, I will now search PubMed abstracts to see if there is any scientific literature that links tanespimycin to cardiac fibrosis.",
            "tool_name_4": "search_pubmed_abstracts",
            "tool_args_4": {
              "request": {
                "term": "tanespimycin cardiac fibrosis"
              }
            },
            "observation_4": "1. J Pharmacol Sci. 2021 Oct;147(2):192-199. doi: 10.1016/j.jphs.2021.06.009.\nEpub  2021 Jun 25.\n\nEffects of 17-AAG on the RIP1/RIP3/MLKL pathway during the development of heart \nfailure following myocardial infarction in rats.\n\nMarunouchi T(1), Ito T(1), Onda S(1), Kyo L(1), Takahashi K(1), Uchida M(1), \nYano E(1), Tanonaka K(2).\n\nAuthor information:\n(1)Department of Molecular and Cellular Pharmacology, Tokyo University of \nPharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo, 192-0392, Japan.\n(2)Department of Molecular and Cellular Pharmacology, Tokyo University of \nPharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo, 192-0392, Japan. \nElectronic address: tanonaka@toyaku.ac.jp.\n\nIn a previous study, we suggested that the Hsp90 inhibitor 17-AAG prevents \ncardiac dysfunction in the failing heart following myocardial infarction in \nrats. Although it is assumed that the RIP1/RIP3/MLKL necroptotic pathway, which \ncomprises client proteins for Hsp90, is involved; however, the relationship \nbetween the cardioprotective effects of 17-AAG and the activity of the cardiac \nRIP1/RIP3/MLKL necrosome-associated proteins in the failing heart following \nmyocardial infarction remained unclear. Therefore, the levels of phosphorylated \nMLKL after myocardial infarction with or without Hsp90 inhibitor treatment were \nmeasured. Myocardial infarction was induced by ligation of the coronary artery \n(CAL) in Wistar rats. 17-AAG was injected from the 2nd to the 8th week after \nmyocardial infarction. The administration of 17-AAG attenuated the cardiac \ndysfunction, hypertrophy, and fibrosis at the 8th week after CAL, simultaneously \nlessening the increases in the expression and phosphorylation levels of RIP1, \nRIP3, and MLKL in the area of the left ventricular muscle without infarct. These \nresults indicate that the activation of the RIP1/RIP3/MLKL pathway is a common \nevent in the development of chronic heart failure. Furthermore, our findings \nsuggest that the effects of 17-AAG treatment on the improvement of cardiac \nfunction in rats after myocardial infarction is related to the attenuation of \nthis RIP1/RIP3/MLKL pathway.\n\nCopyright \u00a9 2021 The Authors. Production and hosting by Elsevier B.V. All rights \nreserved.\n\nDOI: 10.1016/j.jphs.2021.06.009\nPMID: 34384567 [Indexed for MEDLINE]\n\nConflict of interest statement: Declaration of competing interest The authors \ndeclare that they have no competing interest.\n\n\n2. J Cardiovasc Pharmacol. 2021 Jun 1;77(6):822-829. doi: \n10.1097/FJC.0000000000001017.\n\nHsp90 Inhibitor Attenuates the Development of Pathophysiological Cardiac \nFibrosis in Mouse Hypertrophy via Suppression of the Calcineurin-NFAT and \nc-Raf-Erk Pathways.\n\nMarunouchi T(1), Nakashima M, Ebitani S, Umezu S, Karasawa K, Yano E, Tanonaka \nK.\n\nAuthor information:\n(1)Department of Molecular and Cellular Pharmacology, Tokyo University of \nPharmacy and Life Sciences.\n\nIn the previous study, we showed that an Hsp90 inhibitor, \n17-(allylamino)-17-demethoxygeldanamycin (17-AAG), attenuates hypertrophic \nremodeling of cardiomyocytes during the development of heart failure. In this \npresent study, we investigated the effects of 17-AAG on cardiac fibrosis during \nthe development of heart failure. We used pressure-loaded cardiac hypertrophic \nmice prepared by constriction of the transverse aorta (TAC), which induces \nsignificant cardiac fibrosis without scar tissue. From the sixth week after the \nTAC operation, vehicle or 17-AAG was administered intraperitoneally twice a \nweek. Eight weeks after the operation, the vehicle-treated animals showed \nchronic heart failure. On the other hand, cardiac deterioration of the \n17-AAG-treated animals was attenuated. In 17-AAG-treated animals, when the \ndegree of fibrosis was observed by histological staining, their volume of \nfibrosis was found to be reduced. The content of calcineurin, an Hsp90 client \nprotein, and the level of dephosphorylated NFATc2, a transcription factor in the \ncardiac fibroblasts, in the TAC mice was reduced by treatment with 17-AAG. \nFurthermore, c-Raf and Erk signaling, indicators for cell proliferation and \ncollagen synthesis, was also attenuated. In in vitro experiments, the \nproliferation and collagen synthesis of the cultured cardiac fibroblasts were \nattenuated by the presence of 17-AAG. When cardiac fibroblasts were incubated \nwith angiotensin II, calcineurin-NFATc2 and c-Raf-Erk signaling in the cells \nwere activated. These activations were attenuated by 17-AAG. Our findings \nsuggest that suppression of the calcineurin-NFAT and c-Raf-Erk pathways may \npartially contribute to the attenuation of myocardial fibrosis caused by \ntreatment with 17-AAG. Therefore, our data imply that the Hsp90 inhibitor may \nhave potential for novel therapeutic strategy for the treatment of heart \nfailure.\n\nCopyright \u00a9 2021 Wolters Kluwer Health, Inc. All rights reserved.\n\nDOI: 10.1097/FJC.0000000000001017\nPMID: 34016843 [Indexed for MEDLINE]\n\nConflict of interest statement: The authors report no conflicts of interest.\n\n\n3. Eur Respir J. 2017 Feb 23;49(2):1501941. doi: 10.1183/13993003.01941-2015.\nPrint  2017 Feb.\n\nAmplified canonical transforming growth factor-\u03b2 signalling via heat shock \nprotein 90 in pulmonary fibrosis.\n\nSibinska Z(1)(2), Tian X(1)(2), Korfei M(1), Kojonazarov B(1), Kolb JS(1), \nKlepetko W(3)(4), Kosanovic D(1), Wygrecka M(1)(5), Ghofrani HA(1), Weissmann \nN(1), Grimminger F(1), Seeger W(1)(6), Guenther A(1)(3)(7), Schermuly RT(8).\n\nAuthor information:\n(1)Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German \nCenter for Lung Research (DZL), Giessen, Germany.\n(2)Both authors contributed equally.\n(3)Agaplesion Lung Clinic Waldhof Elgershausen, Greifenstein, Germany.\n(4)Vienna Medical University, Vienna, Austria.\n(5)Dept of Biochemistry, Faculty of Medicine, University of Giessen, Giessen, \nGermany.\n(6)Max-Planck-Institute for Heart and Lung Research, Bad Nauheim, Germany.\n(7)European IPF Network and European IPF Registry, Giessen, Germany.\n(8)Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German \nCenter for Lung Research (DZL), Giessen, Germany \nralph.schermuly@innere.med.uni-giessen.de.\n\nComment in\n    Eur Respir J. 2017 Feb 23;49(2):1602152. doi: 10.1183/13993003.02152-2016.\n\nInterstitial lung fibroblast activation coupled with extracellular matrix \nproduction is a pathological signature of idiopathic pulmonary fibrosis (IPF), \nand is governed by transforming growth factor (TGF)-\u03b2/Smad signalling. We sought \nto define the role of heat shock protein (HSP)90 in profibrotic responses in IPF \nand to determine the therapeutic effects of HSP90 inhibition in a murine model \nof pulmonary fibrosis.We investigated the effects of HSP90 inhibition in vitro \nby applying 17-AAG (17-allylamino-17-demethoxygeldanamycin) to lung fibroblasts \nand A549 cells and in vivo by administering 17-DMAG \n(17-dimethylaminoethylamino-17-demethoxygeldanamycin) to mice with \nbleomycin-induced pulmonary fibrosis.HSP90 expression was increased in \n(myo)fibroblasts from fibrotic human and mouse lungs compared with controls. \n17-AAG inhibited TGF-\u03b21-induced extracellular matrix production and \ntransdifferentiation of lung fibroblasts and epithelial-mesenchymal transition \nof A549 cells. The antifibrotic effects were associated with TGF-\u03b2 receptor \ndisruption and inhibition of Smad2/3 activation. Co-immunoprecipitation revealed \nthat HSP90\u03b2 interacted with TGF-\u03b2 receptor II and stabilised TGF-\u03b2 receptors. \nFurthermore, 17-DMAG improved lung function and decreased fibrosis and matrix \nmetalloproteinase activity in the lungs of bleomycin-challenged mice.In \nconclusion, this is the first study to demonstrate that HSP90 inhibition blocks \npulmonary fibroblast activation and ameliorates bleomycin-induced pulmonary \nfibrosis in mice.\n\nCopyright \u00a9ERS 2017.\n\nDOI: 10.1183/13993003.01941-2015\nPMID: 28182573 [Indexed for MEDLINE]"
          },
          "reasoning": "Tanespimycin (also known as 17-AAG) is a heat shock protein 90 (HSP90) inhibitor, primarily developed as an anticancer agent and has reached Phase 3 clinical trials for indications such as multiple myeloma. While its primary indications are in oncology, its mechanism of action via HSP90 inhibition has broader implications.\n\nA search of ChEMBL bioactivities and drug indications did not reveal any direct links to cardiac fibrosis or cardiovascular diseases. However, a targeted search of PubMed abstracts provided highly relevant preclinical evidence:\n1.  A 2021 study in the Journal of Pharmacological Sciences demonstrated that 17-AAG attenuated cardiac dysfunction, hypertrophy, and fibrosis in a rat model of heart failure following myocardial infarction. The study suggested that its cardioprotective effects are related to the attenuation of the RIP1/RIP3/MLKL necroptotic pathway, which involves HSP90 client proteins.\n2.  Another 2021 study in the Journal of Cardiovascular Pharmacology showed that 17-AAG attenuated the development of pathophysiological cardiac fibrosis in a mouse model of hypertrophy induced by transverse aortic constriction (TAC). This study indicated that the anti-fibrotic effects were associated with the suppression of the calcineurin-NFAT and c-Raf-Erk pathways in cardiac fibroblasts.\n3.  A 2017 study in the European Respiratory Journal, while focusing on pulmonary fibrosis, showed that HSP90 inhibition by 17-AAG blocked fibroblast activation and ameliorated bleomycin-induced pulmonary fibrosis in mice. This provides general support for the anti-fibrotic potential of HSP90 inhibitors.\n\nThese studies provide strong preclinical evidence that tanespimycin, through its action as an HSP90 inhibitor, can reduce cardiac fibrosis in animal models of heart failure and hypertrophy. The mechanisms elucidated (RIP1/RIP3/MLKL, calcineurin-NFAT, c-Raf-Erk pathways) are relevant to fibrotic processes. However, it is important to note that these are animal studies, and there is no available data from human clinical trials specifically for cardiac fibrosis.",
          "predicted_efficacy": 0.65,
          "confidence": 0.85
        }
      },
      "toxicity_screening": {
        "result": {
          "trajectory": {
            "thought_0": "I need to find the PubChem CID for tanespimycin to then use the `get_toxicity_data` tool. I will start by searching for the compound using its name.",
            "tool_name_0": "PUBCHEM__search_compounds",
            "tool_args_0": {
              "request": {
                "query": "tanespimycin",
                "search_type": "name"
              }
            },
            "observation_0": "{\n  \"query\": \"tanespimycin\",\n  \"search_type\": \"name\",\n  \"total_found\": 1,\n  \"details\": {\n    \"PropertyTable\": {\n      \"Properties\": [\n        {\n          \"CID\": 6505803,\n          \"MolecularFormula\": \"C31H43N3O8\",\n          \"MolecularWeight\": \"585.7\",\n          \"CanonicalSMILES\": \"CC1CC(C(C(C=C(C(C(C=CC=C(C(=O)NC2=CC(=O)C(=C(C1)C2=O)NCC=C)C)OC)OC(=O)N)C)C)O)OC\",\n          \"IUPACName\": \"[(4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-19-(prop-2-enylamino)-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl] carbamate\"\n        }\n      ]\n    }\n  }\n}",
            "thought_1": "I have successfully found the PubChem CID for tanespimycin, which is 6505803. Now I can use this CID to get the toxicity data using the `PUBCHEM__get_toxicity_data` tool.",
            "tool_name_1": "PUBCHEM__get_toxicity_data",
            "tool_args_1": {
              "request": {
                "cid": 6505803
              }
            },
            "observation_1": "{\n  \"Fault\": {\n    \"Code\": \"PUGVIEW.NotFound\",\n    \"Message\": \"No data found\"\n  }\n}",
            "thought_2": "The `PUBCHEM__get_toxicity_data` tool did not return any data. I will now try to find bioassay results for tanespimycin in PubChem using `PUBCHEM__get_bioassay_results` to see if there are any screening assays that might provide information about its toxicity or cellular effects, specifically looking for \"percent remaining cells\" or similar metrics.",
            "tool_name_2": "PUBCHEM__get_bioassay_results",
            "tool_args_2": {
              "request": {
                "cid": 6505803
              }
            },
            "observation_2": "{\n  \"Table\": {\n    \"Columns\": {\n      \"Column\": [\n        \"AID\",\n        \"Panel Member ID\",\n        \"SID\",\n        \"CID\",\n        \"Activity Outcome\",\n        \"Target GI\",\n        \"Target GeneID\",\n        \"Activity Value [uM]\",\n        \"Activity Name\",\n        \"Assay Name\",\n        \"Assay Type\",\n        \"PubMed ID\",\n        \"RNAi\"\n      ]\n    },\n    \"Row\": [\n      {\n        \"Cell\": [\n          \"1\",\n          \"\",\n          \"574817\",\n          \"6505803\",\n          \"Active\",\n          \"\",\n          \"\",\n          \"\",\n          \"\",\n          \"NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line\",\n          \"Confirmatory\",\n          \"\",\n          \"\"\n        ]\n      },\n      {\n        \"Cell\": [\n          \"3\",\n          \"\",\n          \"574817\",\n          \"6505803\",\n          \"Inactive\",\n          \"\",\n          \"\",\n          \"\",\n          \"\",\n          \"NCI human tumor cell line growth inhibition assay. Data for the NCI-H226 Non-Small Cell Lung cell line\",\n          \"Confirmatory\",\n          \"\",\n          \"\"\n        ]\n      },\n      {\n        \"Cell\": [\n          \"5\",\n          \"\",\n          \"574817\",\n          \"6505803\",\n          \"Active\",\n          \"\",\n          \"\",\n          \"\",\n          \"\",\n          \"NCI human tumor cell line growth inhibition assay. Data for the NCI-H322M Non-Small Cell Lung cell line\",\n          \"Confirmatory\",\n          \"\",\n          \"\"\n        ]\n      },\n      {\n        \"Cell\": [\n          \"7\",\n          \"\",\n          \"574817\",\n          \"6505803\",\n          \"Active\",\n          \"\",\n          \"\",\n          \"\",\n          \"\",\n          \"NCI human tumor cell line growth inhibition assay. Data for the NCI-H460 Non-Small Cell Lung cell line\",\n          \"Confirmatory\",\n          \"\",\n          \"\"\n        ]\n      },\n      {\n        \"Cell\": [\n          \"9\",\n          \"\",\n          \"574817\",\n          \"6505803\",\n          \"Active\",\n          \"\",\n          \"\",\n          \"\",\n          \"\",\n          \"NCI human tumor cell line growth inhibition assay. Data for the HOP-62 Non-Small Cell Lung cell line\",\n          \"Confirmatory\",\n          \"\",\n          \"\"\n        ]\n      },\n      {\n        \"Cell\": [\n          \"13\",\n          \"\",\n          \"574817\",\n          \"6505803\",\n          \"Inactive\",\n          \"\",\n          \"\",\n          \"\",\n          \"\",\n          \"NCI human tumor cell line growth inhibition assay. Data for the HOP-92 Non-Small Cell Lung cell line\",\n          \"Confirmatory\",\n          \"\",\n          \"\"\n        ]\n      },\n      {\n        \"Cell\": [\n          \"15\",\n          \"\",\n          \"574817\",\n          \"6505803\",\n          \"Active\",\n          \"\",\n          \"\",\n          \"\",\n          \"\",\n          \"NCI human tumor cell line growth inhibition assay. Data for the NCI-H522 Non-Small Cell Lung cell line\",\n          \"Confirmatory\",\n          \"\",\n          \"\"\n        ]\n      },\n      {\n        \"Cell\": [\n          \"19\",\n          \"\",\n          \"574817\",\n          \"6505803\",\n          \"Active\",\n          \"\",\n          \"\",\n          \"\",\n          \"\",\n          \"NCI human tumor cell line growth inhibition assay. Data for the A549/ATCC Non-Small Cell Lung cell line\",\n          \"Confirmatory\",\n          \"\",\n          \"\"\n        ]\n      },\n      {\n        \"Cell\": [\n          \"21\",\n          \"\",\n          \"574817\",\n          \"6505803\",\n          \"Inactive\",\n          \"\",\n          \"\",\n          \"\",\n          \"\",\n          \"NCI human tumor cell line growth inhibition assay. Data for the EKVX Non-Small Cell Lung cell line\",\n          \"Confirmatory\",\n          \"\",\n          \"\"\n        ]\n      },\n      {\n        \"Cell\": [\n          \"23\",\n          \"\",\n          \"574817\",\n          \"6505803\",\n          \"Active\",\n          \"\",\n          \"\",\n          \"\",\n          \"\",\n          \"NCI human tumor cell line growth inhibition assay. Data for the LOX IMVI Melanoma cell line\",\n          \"Confirmatory\",\n          \"\",\n          \"\"\n        ]\n      }\n    ]\n  }\n}",
            "thought_3": "The previous step successfully retrieved bioassay results for tanespimycin from PubChem. The results show several \"NCI human tumor cell line growth inhibition assay\" entries, some with \"Active\" and some with \"Inactive\" activity outcomes. These assays are relevant to estimating toxicity in a screening assay, as they measure cell growth inhibition. However, the current output does not directly provide a \"percent remaining cells\" value. It only indicates \"Active\" or \"Inactive\" and doesn't show the specific data points.\n\nTo get more detailed information about these assays, specifically the \"percent remaining cells\" or similar quantitative measures of cell viability/growth, I need to investigate the individual assays. I can use the `PUBCHEM__get_bioassay_info` tool with the AID (Assay ID) from the retrieved results. I will start with AID 1, which is marked as \"Active\" for the NCI-H23 Non-Small Cell Lung cell line. This might provide details about the assay methodology and reported values.",
            "tool_name_3": "PUBCHEM__get_bioassay_info",
            "tool_args_3": {
              "request": {
                "aid": 1
              }
            },
            "observation_3": "{\n  \"PC_AssayContainer\": [\n    {\n      \"assay\": {\n        \"descr\": {\n          \"aid\": {\n            \"id\": 1,\n            \"version\": 9\n          },\n          \"aid_source\": {\n            \"db\": {\n              \"name\": \"DTP/NCI\",\n              \"source_id\": {\n                \"str\": \"NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line\"\n              }\n            }\n          },\n          \"name\": \"NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line\",\n          \"description\": [\n            \"Growth inhibition of the NCI-H23 human Non-Small Cell Lung tumor cell line is measured as a screen for anti-cancer activity. Cells are grown in 96 well plates and exposed to the test compound for 48 hours. Compounds are tested at 5 different concentrations and three endpoints are estimated from this dose response curve: GI50, concentration required for 50% inhibition of growth, TGI, the concentration requires for complete inhibition of growth, and LC50, the concentration required for 50% reduction in cell number. These estimates are done by simple linear interpolation between the concentrations that surround the approriate level. If a compound doesn't cause inhibition to the appropriate level, the endpoint is set to the highest concentration tested.\"\n          ],\n          \"protocol\": [\n            \"\"\n          ],\n          \"comment\": [\n            \"These data are a subset of the data from the NCI human tumor cell line screen. Compounds are identified by the NCI NSC number. In the NCI numbering system, NCI-H23 is panel number 1, cell number 1\",\n            \"Basically compounds  with LogGI50 (unit M) less than -6 were considered as active. Activity score was based on increasing values of -LogGI50.\"\n          ],\n          \"xref\": [\n            {\n              \"xref\": {\n                \"dburl\": \"http://dtp.nci.nih.gov/\"\n              }\n            },\n            {\n              \"xref\": {\n                \"asurl\": \"http://dtp.nci.nih.gov/branches/btb/ivclsp.html\"\n              }\n            },\n            {\n              \"xref\": {\n                \"pmid\": 3335022\n              }\n            },\n            {\n              \"xref\": {\n                \"pmid\": 1462164\n              }\n            },\n            {\n              \"xref\": {\n                \"pmid\": 3051021\n              }\n            }\n          ],\n          \"results\": [\n            {\n              \"tid\": 1,\n              \"name\": \"LogGI50_M\",\n              \"description\": [\n                \"Log of the GI50 result, unit: M.\"\n              ],\n              \"type\": 1\n            },\n            {\n              \"tid\": 2,\n              \"name\": \"LogGI50_u\",\n              \"description\": [\n                \"Log of the GI50 result, unit: ug/mL.\"\n              ],\n              \"type\": 1\n            },\n            {\n              \"tid\": 3,\n              \"name\": \"LogGI50_V\",\n              \"description\": [\n                \"Log of the GI50 result, unit: Volumetric.\"\n              ],\n              \"type\": 1\n            },\n            {\n              \"tid\": 4,\n              \"name\": \"IndnGI50\",\n              \"description\": [\n                \"Number of tests averaged for the GI50 value for this NSC and cell line.\"\n              ],\n              \"type\": 2\n            },\n            {\n              \"tid\": 5,\n              \"name\": \"StddevGI50\",\n              \"description\": [\n                \"Standard Deviation of the Log10 of the GI50 result averaged across all tests for this NSC and cell line.\"\n              ],\n              \"type\": 1\n            },\n            {\n              \"tid\": 6,\n              \"name\": \"LogTGI_M\",\n              \"description\": [\n                \"Log of the TGI result, unit: M.\"\n              ],\n              \"type\": 1\n            },\n            {\n              \"tid\": 7,\n              \"name\": \"LogTGI_u\",\n              \"description\": [\n                \"Log of the TGI result, unit: ug/mL.\"\n              ],\n              \"type\": 1\n            },\n            {\n              \"tid\": 8,\n              \"name\": \"LogTGI_V\",\n              \"description\": [\n                \"Log of the TGI result, unit: Volumetric.\"\n              ],\n              \"type\": 1\n            },\n            {\n              \"tid\": 9,\n              \"name\": \"IndnTGI\",\n              \"description\": [\n                \"Number of tests averaged for the TGI value for this NSC and cell line.\"\n              ],\n              \"type\": 2\n            },\n            {\n              \"tid\": 10,\n              \"name\": \"StddevTGI\",\n              \"description\": [\n                \"Standard Deviation of the Log10 of the TGI result averaged across all tests for this NSC and cell line.\"\n              ],\n              \"type\": 1\n            }\n          ],\n          \"revision\": 1,\n          \"activity_outcome_method\": 2,\n          \"project_category\": 255,\n          \"assay_group\": [\n            \"NCI-60_DOSERESP\"\n          ]\n        }\n      }\n    }\n  ]\n}",
            "thought_4": "The `PUBCHEM__get_toxicity_data` tool did not return any information, and while `PUBCHEM__get_bioassay_results` showed that tanespimycin is active in NCI human tumor cell line growth inhibition assays, it did not provide specific quantitative values like \"percent remaining cells\" or GI50/TGI/LC50. The `PUBCHEM__get_bioassay_info` for AID 1 explained the assay and its endpoints (GI50, TGI, LC50) but also did not provide the specific values for tanespimycin. It did, however, list relevant PubMed IDs. My next step is to search PubMed for articles related to tanespimycin and the NCI growth inhibition assay to find the quantitative results.",
            "tool_name_4": "search_pubmed_abstracts",
            "tool_args_4": {
              "request": {
                "term": "tanespimycin NCI human tumor cell line growth inhibition assay"
              }
            },
            "observation_4": "1. Cell Death Dis. 2018 Feb 7;9(2):165. doi: 10.1038/s41419-017-0247-5.\n\nThe antitumor natural product tanshinone IIA inhibits protein kinase C and acts \nsynergistically with 17-AAG.\n\nLv C(1), Zeng HW(2), Wang JX(2), Yuan X(2), Zhang C(3), Fang T(4), Yang PM(1), \nWu T(1), Zhou YD(5)(6), Nagle DG(5)(7), Zhang WD(8)(9).\n\nAuthor information:\n(1)Shanghai Institute of Pharmaceutical Industry, China State Institute of \nPharmaceutical Industry, Shanghai, 201203, P.R. China.\n(2)School of Pharmacy, Second Military Medical University, Shanghai, 200433, \nP.R. China.\n(3)School of Pharmaceutical Sciences, Zhengzhou University, Henan, 450001, P.R. \nChina.\n(4)School of Pharmacy, Fujian University of Traditional Chinese Medicine, \nFujian, 350108, P.R. China.\n(5)Institute of Interdisciplinary Integrative Biomedical Research, Shanghai \nUniversity of Traditional Chinese Medicine, Shanghai, 201203, China.\n(6)Department of Chemistry and Biochemistry, College of Liberal Arts, University \nof Mississippi, University, Mississippi, MS, 38677-1848, USA.\n(7)Department of BioMolecular Sciences and Research Institute of Pharmaceutical \nSciences, School of Pharmacy, University of Mississippi, University, \nMississippi, MS, 38677-1848, USA.\n(8)Shanghai Institute of Pharmaceutical Industry, China State Institute of \nPharmaceutical Industry, Shanghai, 201203, P.R. China. wdzhangy@hotmail.com.\n(9)School of Pharmacy, Second Military Medical University, Shanghai, 200433, \nP.R. China. wdzhangy@hotmail.com.\n\nTanshinone IIA (Tan IIA), the primary bioactive compound derived from the \ntraditional Chinese medicine (TCM) Salvia miltiorrhiza Bunge, has been reported \nto possess antitumor activity. However, its antitumor mechanisms are not fully \nunderstood. To resolve the potential antitumor mechanism(s) of Tan IIA, its gene \nexpression profiles from our database was analyzed by connectivity map (CMAP) \nand the CMAP-based mechanistic predictions were confirmed/validated in further \nstudies. Specifically, Tan IIA inhibited total protein kinase C (PKC) activity \nand selectively suppressed the expression of cytosolic and plasma membrane PKC \nisoforms \u03b6 and \u03b5. The Ras/MAPK pathway that is closely regulated by the PKC \nsignaling is also inhibited by Tan IIA. While Tan IIA did not inhibit heat shock \nprotein 90 (Hsp90), it synergistically enhanced the antitumor efficacy of the \nHsp90 inhibitors 17-AAG and ganetespib in human breast cancer MCF-7 cells. In \naddition, Tan IIA significantly inhibited PI3K/Akt/mTOR signaling, and induced \nboth cell cycle arrest and autophagy. Collectively, these studies provide new \ninsights into the molecular mechanisms responsible for antitumor activity of Tan \nIIA.\n\nDOI: 10.1038/s41419-017-0247-5\nPMCID: PMC5833361\nPMID: 29416003 [Indexed for MEDLINE]\n\nConflict of interest statement: The authors declare that they have no conflict \nof interest.\n\n\n2. PLoS One. 2015 Jun 1;10(6):e0128143. doi: 10.1371/journal.pone.0128143. \neCollection 2015.\n\nDifferential CARM1 Isoform Expression in Subcellular Compartments and among \nMalignant and Benign Breast Tumors.\n\nShlensky D(1), Mirrielees JA(1), Zhao Z(2), Wang L(2), Mahajan A(3), Yu M(4), \nSherer NM(2), Wilke LG(1), Xu W(2).\n\nAuthor information:\n(1)Department of Surgery, University of Wisconsin School of Medicine and Public \nHealth, Madison, Wisconsin, United States of America.\n(2)Department of Oncology, University of Wisconsin School of Medicine and Public \nHealth, Madison, Wisconsin, United States of America.\n(3)Department of Pathology and Laboratory Medicine, University of Wisconsin \nSchool of Medicine and Public Health, Madison, Wisconsin, United States of \nAmerica.\n(4)Department of Biostatistics and Medical Informatics, University of Wisconsin \nSchool of Medicine and Public Health, Madison, Wisconsin, United States of \nAmerica.\n\nErratum in\n    PLoS One. 2015 Jun 25;10(6):e0131955. doi: 10.1371/journal.pone.0131955.\n\nPURPOSE: Coactivator-associated arginine methyltransferase 1 (CARM1) is a \ncoactivator for ER\u03b1 and cancer-relevant transcription factors, and can methylate \ndiverse cellular targets including histones. CARM1 is expressed in one of two \nalternative splice isoforms, full-length CARM1 (CARM1FL) and truncated CARM1 \n(CARM1\u0394E15). CARM1FL and CARM1\u0394E15 function differently in transcriptional \nregulation, protein methylation, and mediation of pre-mRNA splicing in cellular \nmodels.\nMETHODS: To investigate the functional roles and the prognosis potential of \nCARM1 alternative spliced isoforms in breast cancer, we used recently developed \nantibodies to detect differential CARM1 isoform expression in subcellular \ncompartments and among malignant and benign breast tumors.\nRESULTS: Immunofluorescence in MDA-MB-231 and BG-1 cell lines demonstrated that \nCARM1\u0394E15 is the dominant isoform expressed in the cytoplasm, and CARM1FL is \nmore nuclear localized. CARM1\u0394E15 was found to be more sensitive to Hsp90 \ninhibition than CARM1FL, indicating that the truncated isoform may be the \noncogenic form. Clinical cancer samples did not have significantly higher \nexpression of CARM1FL or CARM1\u0394E15 than benign breast samples at the level of \nmRNA or histology. Furthermore neither CARM1FL nor CARM1\u0394E15 expression \ncorrelated with breast cancer molecular subtypes, tumor size, or lymph node \ninvolvement.\nCONCLUSIONS: The analysis presented here lends new insights into the possible \noncogenic role of CARM1\u0394E15. This study also demonstrates no obvious association \nof CARM1 isoform expression and clinical correlates in breast cancer. Recent \nstudies, however, have shown that CARM1 expression correlates with poor \nprognosis, indicating a need for further studies of both CARM1 isoforms in a \nlarge cohort of breast cancer specimens.\n\nDOI: 10.1371/journal.pone.0128143\nPMCID: PMC4451767\nPMID: 26030442 [Indexed for MEDLINE]\n\nConflict of interest statement: Competing Interests: The authors have declared \nthat no competing interests exist.\n\n\n3. Eur Urol. 2014 Jul;66(1):145-55. doi: 10.1016/j.eururo.2013.12.019. Epub 2013 \nDec 29.\n\nSuppression of heat shock protein 27 using OGX-427 induces endoplasmic reticulum \nstress and potentiates heat shock protein 90 inhibitors to delay \ncastrate-resistant prostate cancer.\n\nLamoureux F(1), Thomas C(1), Yin MJ(2), Fazli L(1), Zoubeidi A(1), Gleave ME(3).\n\nAuthor information:\n(1)The Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, \nCanada.\n(2)Oncology Research, Pfizer Worldwide Research & Development, San Diego, CA, \nUSA.\n(3)The Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, \nCanada. Electronic address: m.gleave@ubc.ca.\n\nErratum in\n    Eur Urol. 2016 Jul;70(1):e27-e28. doi: 10.1016/j.eururo.2016.03.014.\n\nBACKGROUND: Although prostate cancer responds initially to androgen ablation \ntherapies, progression to castration-resistant prostate cancer (CRPC) frequently \noccurs. Heat shock protein (Hsp) 90 inhibition is a rational therapeutic \nstrategy for CRPC that targets key proteins such as androgen receptor (AR) and \nprotein kinase B (Akt); however, most Hsp90 inhibitors trigger elevation of \nstress proteins like Hsp27 that confer tumor cell survival and treatment \nresistance.\nOBJECTIVE: We hypothesized that cotargeting the cytoprotective chaperone Hsp27 \nand Hsp90 would amplify endoplasmic reticulum (ER) stress and treatment-induced \ncell death in cancer.\nDESIGN, SETTING, AND PARTICIPANTS: Inducible and constitutive Hsp27 and other \nHSPs were measured by real-time reverse transcription-polymerase chain reaction \nand immunoblot assays. The combinations of OGX-427 with Hsp90 inhibitors were \nevaluated in vitro for LNCaP cell growth and apoptosis and in vivo in CRPC LNCaP \nxenograft models.\nOUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Tumor volumes were compared using \nthe Kruskal-Wallis test. Overall survival was analyzed using Kaplan-Meier \ncurves, and statistical significance was assessed with the log-rank test.\nRESULTS AND LIMITATIONS: Hsp90 inhibitors induced expression of HSPs in tumor \ncells and tissues in a dose- and time-dependent manner; in particular, Hsp27 \nmRNA and protein levels increased threefold. In vitro, OGX-427 synergistically \nenhanced Hsp90 inhibitor-induced suppression of cell growth and induced \napoptosis by 60% as measured by increased sub-G1 fraction and poly(ADP-ribose) \npolymerase cleavage. These biologic events were accompanied by decreased \nexpression of HSPs, Akt, AR, and prostate-specific antigen, and induction of ER \nstress markers (cleaved activating transcription factor 6, glucose-regulated \nprotein 78, and DNA-damage-inducible transcript 3). In vivo, OGX-427 potentiated \nthe anticancer effects of Hsp90 inhibitor PF-04929113 (orally, 25mg/kg) to \ninhibit tumor growth and prolong survival in CRPC LNCaP xenografts.\nCONCLUSIONS: HSP90 inhibitor-mediated induction of Hsp27 expression can be \nattenuated by OGX-427, resulting in increased ER stress and apoptosis, and \nsynergistic inhibition of CRPC tumor growth.\nPATIENT SUMMARY: This study supports the development of targeted strategies \nusing OGX-427 in combination with Hsp90 inhibitors to improve patient outcome in \nCRPC.\n\nCopyright \u00a9 2013 European Association of Urology. All rights reserved.\n\nDOI: 10.1016/j.eururo.2013.12.019\nPMCID: PMC4079118\nPMID: 24411988 [Indexed for MEDLINE]\n\n\n4. Oncotarget. 2013 Aug;4(8):1185-98. doi: 10.18632/oncotarget.1162.\n\nCombining trail with PI3 kinase or HSP90 inhibitors enhances apoptosis in \ncolorectal cancer cells via suppression of survival signaling.\n\nSaturno G(1), Valenti M, De Haven Brandon A, Thomas GV, Eccles S, Clarke PA, \nWorkman P.\n\nAuthor information:\n(1)Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, \nThe Institute of Cancer Research, London, UK.\n\nTRAIL has been shown to induce apoptosis in cancer cells, but in some cases they \nfail to respond to this ligand. We explored the ability of representative \nphosphatidylinositol-3-kinase (PI3 Kinase)/mTOR and HSP90 inhibitors to overcome \nTRAIL resistance by increasing apoptosis in colorectal cancer models. We \ndetermined the sensitivity of 27 human colorectal cancer and 2 non-transformed \ncolon epithelial cell lines to TRAIL treatment. A subset of the cancer cell \nlines with a range of responses to TRAIL was selected from the panel for \ntreatment with TRAIL combined with the PI3 Kinase/mTOR inhibitor PI-103 or the \nHSP90 inhibitor 17-AAG (tanespimycin). Two TRAIL-resistant cell lines were \nselected for in vivo combination studies with TRAIL and 17-AAG. We found that 13 \ncolorectal cancer cell lines and the 2 non-transformed colon epithelial cell \nlines were resistant to TRAIL. We demonstrated that co-treatment of TRAIL and \nPI-103 or 17-AAG was synergistic or additive and significantly enhanced \napoptosis in colorectal cancer cells. This was associated with decreased \nexpression or activity of survival protein biomarkers such as ERBB2, AKT, IKK\u03b1 \nand XIAP. In contrast, the effect of the combination treatments in \nnon-transformed colon cells was minimal. We show here for the first time that \nco-treatment in vivo with TRAIL and 17-AAG in two TRAIL-resistant human \ncolorectal cancer xenograft models resulted in significantly greater tumor \ngrowth inhibition compared to single treatments. We propose that combining TRAIL \nwith PI3 Kinase/mTOR or HSP90 inhibitors has therapeutic potential in the \ntreatment of TRAIL-resistant colorectal cancers.\n\nDOI: 10.18632/oncotarget.1162\nPMCID: PMC3787150\nPMID: 23852390 [Indexed for MEDLINE]\n\nConflict of interest statement: The authors declare a conflict of interest. The \nauthors are employees of The Institute of Cancer Research, which has a \ncommercial interest in the development of PI3 kinase and HSP90 inhibitors and \noperates a rewards-to-inventors scheme. Paul Workman, Paul Clarke, Melanie \nValenti, Alexis De Haven Brandon and Suzanne Eccles have been involved in a \ncommercial collaboration with Yamanouchi (now Astellas Pharma) and with Piramed \nPharma and intellectual property arising from the program has been licensed to \nGenentech. Genentech and Piramed Pharma were acquired by Roche. Paul Workman was \na scientific founder of, consultant to, and Scientific Advisory Board member of \nPiramed Pharma. Professor Paul Workman, Melanie Valenti, Alexis De Haven Brandon \nand Suzanne Eccles have been in a commercial collaboration with Vernalis Ltd and \nintellectual property from this program was licensed to Vernalis Ltd and \nNovartis. Paul Workman has been a consultant to Novartis and Suzanne Eccles is a \nconsultant for Vernalis. Paul Workman has been a scientific founder of, \nconsultant to, and Scientific Advisory Board and Main Board member of Chroma \nTherapeutics. Paul Workman is also a Scientific Advisory Board member for Wilex \nand Nextech Invest Ltd.\n\n\n5. Mol Cancer Ther. 2012 Oct;11(10):2233-42. doi: 10.1158/1535-7163.MCT-11-0987. \nEpub 2012 Aug 14.\n\nAntitumor activity of Triolimus: a novel multidrug-loaded micelle containing \nPaclitaxel, Rapamycin, and 17-AAG.\n\nHasenstein JR(1), Shin HC, Kasmerchak K, Buehler D, Kwon GS, Kozak KR.\n\nAuthor information:\n(1)University of Wisconsin--Madison, School of Medicine and Public Health, \nDepartment of Human Oncology, 1111 Highland Avenue, WIMR 3153, Madison, WI \n53705, USA.\n\nTriolimus is a first-in-class, multidrug-loaded micelle containing paclitaxel, \nrapamycin, and 17-AAG. In this study, we examine the antitumor mechanisms of \naction, efficacy, and toxicity of Triolimus in vitro and in vivo. In vitro \ncytotoxicity testing of Triolimus was conducted using two aggressive \nadenocarcinomas including the lung cancer cell line, A549, and breast cancer \ncell line, MDA-MB-231. The three-drug combination of paclitaxel, rapamycin, and \n17-AAG displayed potent cytotoxic synergy in both A549 and MDA-MB-231 cell \nlines. Mechanistically, the drug combination inhibited both the \nRas/Raf/mitogen-activated protein kinase and PI3K/Akt/mTOR pathways. Triolimus \nwas advanced into tumor xenograft models for assessment of efficacy, toxicity, \nand mechanisms of action. In vivo, a three-infusion schedule of Triolimus \ninhibited A549 and MDA-MB-231 tumor growth far more potently than \npaclitaxel-containing micelles and effected tumor cures in MDA-MB-231 \ntumor-bearing animals. Tumor growth delays resulted from a doubling in tumor \ncell apoptosis and a 50% reduction in tumor cell proliferation compared with \npaclitaxel-containing micelles. Enhanced antitumor efficacy was achieved without \nclinically significant increases in acute toxicity. Thus, Triolimus displays \npotent synergistic activity in vitro and antitumor activity in vivo with \ncomparable toxicity to paclitaxel. These observations provide strong support for \nfurther development of Triolimus and an important proof of concept for safe, \neffective nanoparticle-based delivery of three complementary anticancer agents.\n\nDOI: 10.1158/1535-7163.MCT-11-0987\nPMCID: PMC3469732\nPMID: 22896668 [Indexed for MEDLINE]\n\nConflict of interest statement: The authors have no conflicting financial \ninterests\n\n\n6. Clin Cancer Res. 2012 Sep 15;18(18):4973-85. doi:\n10.1158/1078-0432.CCR-11-2967.  Epub 2012 Jul 17.\n\nGanetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor \nactivity in in vitro and in vivo models of non-small cell lung cancer.\n\nShimamura T(1), Perera SA, Foley KP, Sang J, Rodig SJ, Inoue T, Chen L, Li D, \nCarretero J, Li YC, Sinha P, Carey CD, Borgman CL, Jimenez JP, Meyerson M, Ying \nW, Barsoum J, Wong KK, Shapiro GI.\n\nAuthor information:\n(1)Department of Molecular Pharmacology and Therapeutics, Oncology Institute, \nLoyola University of Chicago, Stritch School of Medicine, Maywood, Illinois, \nUSA.\n\nPURPOSE: We describe the anticancer activity of ganetespib, a novel \nnon-geldanamycin heat shock protein 90 (HSP90) inhibitor, in non-small cell lung \ncancer (NSCLC) models.\nEXPERIMENTAL DESIGN: The activity of ganetespib was compared with that of the \ngeldanamycin 17-AAG in biochemical assays, cell lines, and xenografts, and \nevaluated in an ERBB2 YVMA-driven mouse lung adenocarcinoma model.\nRESULTS: Ganetespib blocked the ability of HSP90 to bind to biotinylated \ngeldanamycin and disrupted the association of HSP90 with its cochaperone, p23, \nmore potently than 17-AAG. In genomically defined NSCLC cell lines, ganetespib \ncaused depletion of receptor tyrosine kinases, extinguishing of downstream \nsignaling, inhibition of proliferation and induction of apoptosis with IC(50) \nvalues ranging 2 to 30 nmol/L, substantially lower than those required for \n17-AAG (20-3,500 nmol/L). Ganetespib was also approximately 20-fold more potent \nin isogenic Ba/F3 pro-B cells rendered IL-3 independent by expression of EGFR \nand ERBB2 mutants. In mice bearing NCI-H1975 (EGFR L858R/T790M) xenografts, \nganetespib was rapidly eliminated from plasma and normal tissues but was \nmaintained in tumor with t(1/2) 58.3 hours, supporting once-weekly dosing \nexperiments, in which ganetespib produced greater tumor growth inhibition than \n17-AAG. However, after a single dose, reexpression of mutant EGFR occurred by 72 \nhours, correlating with reversal of antiproliferative and proapoptotic effects. \nConsecutive day dosing resulted in xenograft regressions, accompanied by more \nsustained pharmacodynamic effects. Ganetespib also showed activity against mouse \nlung adenocarcinomas driven by oncogenic ERBB2 YVMA.\nCONCLUSIONS: Ganetespib has greater potency than 17-AAG and potential efficacy \nagainst several NSCLC subsets, including those harboring EGFR or ERBB2 mutation.\n\n\u00a92012 AACR.\n\nDOI: 10.1158/1078-0432.CCR-11-2967\nPMCID: PMC3477583\nPMID: 22806877 [Indexed for MEDLINE]\n\n\n7. PLoS One. 2011;6(10):e26155. doi: 10.1371/journal.pone.0026155. Epub 2011 Oct \n12.\n\nMagnetic resonance spectroscopy detectable metabolomic fingerprint of response \nto antineoplastic treatment.\n\nLodi A(1), Ronen SM.\n\nAuthor information:\n(1)Department of Radiology and Biomedical Imaging, University of California San \nFrancisco, San Francisco, California, United States of America.\n\nTargeted therapeutic approaches are increasingly being implemented in the \nclinic, but early detection of response frequently presents a challenge as many \nnew therapies lead to inhibition of tumor growth rather than tumor shrinkage. \nDevelopment of novel non-invasive methods to monitor response to treatment is \ntherefore needed. Magnetic resonance spectroscopy (MRS) and magnetic resonance \nspectroscopic imaging are non-invasive imaging methods that can be employed to \nmonitor metabolism, and previous studies indicate that these methods can be \nuseful for monitoring the metabolic consequences of treatment that are \nassociated with early drug target modulation. However, single-metabolite \nbiomarkers are often not specific to a particular therapy. Here we used an \nunbiased 1H MRS-based metabolomics approach to investigate the overall metabolic \nconsequences of treatment with the phosphoinositide 3-kinase inhibitor LY294002 \nand the heat shock protein 90 inhibitor 17AAG in prostate and breast cancer cell \nlines. LY294002 treatment resulted in decreased intracellular lactate, alanine \nfumarate, phosphocholine and glutathione. Following 17AAG treatment, decreased \nintracellular lactate, alanine, fumarate and glutamine were also observed but \nphosphocholine accumulated in every case. Furthermore, citrate, which is \ntypically observed in normal prostate tissue but not in tumors, increased \nfollowing 17AAG treatment in prostate cells. This approach is likely to provide \nfurther information about the complex interactions between signaling and \nmetabolic pathways. It also highlights the potential of MRS-based metabolomics \nto identify metabolic signatures that can specifically inform on molecular drug \naction.\n\nDOI: 10.1371/journal.pone.0026155\nPMCID: PMC3192145\nPMID: 22022547 [Indexed for MEDLINE]\n\nConflict of interest statement: Competing Interests: The authors have declared \nthat no competing interests exist.\n\n\n8. J Thorac Oncol. 2011 Nov;6(11):1784-92. doi: 10.1097/JTO.0b013e31822adfb0.\n\nIdentifying inhibitors of epithelial-mesenchymal transition by connectivity \nmap-based systems approach.\n\nReka AK(1), Kuick R, Kurapati H, Standiford TJ, Omenn GS, Keshamouni VG.\n\nAuthor information:\n(1)Division of Pulmonary and Critical Care Medicine, Department of Internal \nMedicine, University of Michigan Medical Center, Ann Arbor, Michigan 48109, USA.\n\nBACKGROUND: Acquisition of mesenchymal phenotype by epithelial cells by means of \nepithelial-mesenchymal transition (EMT) is considered as an early event in the \nmultistep process of tumor metastasis. Therefore, inhibition of EMT might be a \nrational strategy to prevent metastasis.\nMETHODS: Using the global gene expression profile from a cell culture model of \ntransforming growth factor-\u03b2 (TGF-\u03b2)-induced EMT, we identified potential EMT \ninhibitors. We used a publicly available database (www.broad.mit.edu/cmap) \ncomprising gene expression profiles obtained from multiple different cell lines \nin response to various drugs to derive negative correlations to EMT gene \nexpression profile using Connectivity Map, a pattern matching tool.\nRESULTS: Experimental validation of the identified compounds showed rapamycin as \na novel inhibitor of TGF-\u03b2 signaling along with 17-AAG, a known modulator of \nTGF-\u03b2 pathway. Both of these compounds completely blocked EMT and the associated \nmigratory and invasive phenotype. The other identified compound, LY294002, \ndemonstrated a selective inhibition of mesenchymal markers, cell migration and \ninvasion, without affecting the loss of E-cadherin expression or Smad \nphosphorylation.\nCONCLUSIONS: Our data reveal that rapamycin is a novel modulator of TGF-\u03b2 \nsignaling, and along with 17-AAG and LY294002, could be used as therapeutic \nagent for inhibiting EMT. This study demonstrates the potential of a systems \napproach in identifying novel modulators of a complex biological process.\n\nDOI: 10.1097/JTO.0b013e31822adfb0\nPMCID: PMC3196823\nPMID: 21964532 [Indexed for MEDLINE]\n\n\n9. Nutr Cancer. 2011;63(7):1151-9. doi: 10.1080/01635581.2011.596645. Epub 2011\nAug  29.\n\nSulforaphane potentiates the efficacy of 17-allylamino 17-demethoxygeldanamycin \nagainst pancreatic cancer through enhanced abrogation of Hsp90 chaperone \nfunction.\n\nLi Y(1), Zhang T, Schwartz SJ, Sun D.\n\nAuthor information:\n(1)Department of Pharmaceutical Sciences, College of Pharmacy, University of \nMichigan, Ann Arbor, Michigan 48109, USA.\n\nHeat shock protein 90 (Hsp90), an essential molecular chaperone that regulates \nthe stability of a wide range of oncogenic proteins, is a promising target for \ncancer therapeutics. We investigated the combination efficacy and potential \nmechanisms of sulforaphane, a dietary component from broccoli and broccoli \nsprouts, and 17-allylamino 17-demethoxygeldanamycin (17-AAG), an Hsp90 \ninhibitor, in pancreatic cancer. MTS assay demonstrated that sulforaphane \nsensitized pancreatic cancer cells to 17-AAG in vitro. Caspase-3 was activated \nto 6.4-fold in response to simultaneous treatment with sulforaphane and 17-AAG, \nwhereas 17-AAG alone induced caspase-3 activity to 2-fold compared to control. \nATP binding assay and coimmunoprecipitation revealed that sulforaphane disrupted \nHsp90-p50(Cdc37) interaction, whereas 17-AAG inhibited ATP binding to Hsp90. \nConcomitant use of sulforaphane and 17-AAG synergistically downregulated Hsp90 \nclient proteins in Mia Paca-2 cells. Co-administration of sulforaphane and \n17-AAG in pancreatic cancer xenograft model led to more than 70% inhibition of \nthe tumor growth, whereas 17-AAG alone only suppressed the tumor growth by 50%. \nOur data suggest that sulforaphane potentiates the efficacy of 17-AAG against \npancreatic cancer through enhanced abrogation of Hsp90 function. These findings \nprovide a rationale for further evaluation of broccoli/broccoli sprout \npreparations combined with 17-AAG for better efficacy and lower dose-limiting \ntoxicity in pancreatic cancer.\n\nDOI: 10.1080/01635581.2011.596645\nPMCID: PMC3850054\nPMID: 21875325 [Indexed for MEDLINE]\n\n\n10. Clin Cancer Res. 2011 Apr 15;17(8):2301-13. doi:\n10.1158/1078-0432.CCR-10-3077.  Epub 2011 Feb 24.\n\nA novel HSP90 inhibitor delays castrate-resistant prostate cancer without \naltering serum PSA levels and inhibits osteoclastogenesis.\n\nLamoureux F(1), Thomas C, Yin MJ, Kuruma H, Fazli L, Gleave ME, Zoubeidi A.\n\nAuthor information:\n(1)The Vancouver Prostate Centre, University of British Columbia, Vancouver, \nBritish Columbia, Canada.\n\nErratum in\n    Clin Cancer Res. 2011 Jul 15;17(14):4916.\n\nPURPOSE: Prostate cancer responds initially to antiandrogen therapies; however, \nprogression to castration-resistant disease frequently occurs. Therefore, there \nis an urgent need for novel therapeutic agents that can prevent the emergence of \ncastrate-resistant prostate cancer (CRPC). HSP90 is a molecular chaperone \ninvolved in the stability of many client proteins including Akt and androgen \nreceptor (AR). 17-Allylamino-17-demethoxy-geldanamycin (17-AAG) has been \nreported to inhibit tumor growth in various cancers; however, it induces tumor \nprogression in the bone microenvironment.\nMETHODS: Cell growth, apoptosis, and AR transactivation were examined by crystal \nviolet assay, flow cytometric, and luciferase assays, respectively. The \nconsequence of HSP90 therapy in vivo was evaluated in LNCaP xenograft model. The \nconsequence of PF-04928473 therapy on bone metastasis was studied using an \nosteoclastogenesis in vitro assay.\nRESULTS: PF-04928473 inhibits cell growth in a panel of prostate cancer cells, \ninduces cell-cycle arrest at sub-G(1), and leads to apoptosis and increased \ncaspase-3 activity. These biological events were accompanied by decreased \nactivation of Akt and Erk as well as decreased expression of Her2, and decreased \nAR expression and activation in vitro. In contrast to 17-AAG, PF-04928473 \nabrogates RANKL-induced osteoclast differentiation by affecting NF-\u03baB activation \nand Src phosphorylation. Finally, PF-04929113 inhibited tumor growth and \nprolonged survival compared with controls. Surprisingly, PF-04929113 did not \nreduce serum prostate-specific antigen (PSA) levels in vivo; in parallel, these \ndecrease in tumor volume.\nCONCLUSION: These data identify significant anticancer activity of PF-04929113 \nin CRPC but suggest that serum PSA may not prove useful as pharmacodynamic tool \nfor this drug.\n\n\u00a92011 AACR.\n\nDOI: 10.1158/1078-0432.CCR-10-3077\nPMCID: PMC4437585\nPMID: 21349995 [Indexed for MEDLINE]"
          },
          "reasoning": null,
          "percent_remaining_cells": null,
          "confidence": null
        }
      }
    }
  }
}